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Abstract  
Background: Benzodiazepines are believed to be one of the most overprescribed medications 
worldwide. Inappropriate prescribing of benzodiazepines can lead to serious adverse effects 
including cognitive impairment, falls in the elderly, and decreased motor function. Guidelines 
have been developed to address overprescribing, however analysis of prescribing patterns before 
and after implementing these guidelines shows inappropriate use is still present.  
Objectives: This thesis examined benzodiazepine prescribing patterns in a sample of 
Newfoundland patients. Various definitions for inappropriate prescriptions were used: within 30, 
45 and 60 days of previous prescription. Comparisons were assessed between rural and urban 
areas of Newfoundland, Canada.  
Methods: Patients with a benzodiazepine prescription between 2007 and 2017, through the 
Newfoundland and Labrador Prescription Drug Program, were included in this study. Descriptive 
statistics were used to describe prescribing patterns. Regression analyses were used to examine 
the association between prescribing / usage and age, sex, prescriber specialty and location of 
residence (urban / rural). 
Results: Using the various definitions for inappropriate prescribing, the rate of inappropriate 
prescribing was between 71.7% and 74.9%. Individuals in urban areas had a higher quantity of 
inappropriate prescriptions, less than 30 days apart, compared to those in rural areas.  
Additionally, the percentage of inappropriate prescriptions did not decrease during the ten-year 
timeframe examined.  
Conclusions: Inappropriate prescribing remained prevalent in a Newfoundland and Labrador 
sample. Results from this study highlight that we need to remain vigilant pursuing strategies that 











 Benzodiazepines are commonly overprescribed and can have serious adverse effects. In 
an attempt to reduce overprescribing, national guidelines were introduced. The potential impact 
of these guidelines on prescribing can be explored through examining prescribing rates before 
and after their introduction. This thesis used data from the Newfoundland and Labrador Centre 
for Health Information to determine what prescribing rates were from 2007 to 2017. Findings 
suggest that benzodiazepine prescribing was inappropriate in 71.7% of the prescriptions 
examined. Furthermore, prescriptions were predominantly prescribed by a general practitioner to 
females. Individuals living in urban areas were prescribed a significantly higher quantity of pills 
and for a longer duration than those in rural areas. These findings demonstrate the need for 
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Chapter 1: Introduction 
1.1 Benzodiazepines, 1960s to Present 
 
Benzodiazepines were introduced in 1960 as an anxiolytic with the purpose of replacing 
barbiturates. Barbiturates were associated with serious adverse effects, including acute poisoning, 
addiction (Mehdi, 2012; Roberts and Buckley, 2011), and fatal outcomes due to a narrow 
therapeutic index. As a result of these negative effects, prescribers switched to benzodiazepines 
due to the belief that the adverse effect profile was not as severe as barbiturates. 
Chlordiazepoxide was the first benzodiazepine marketed, under the name Librium, followed by 
diazepam, under the name Valium (Mehdi, 2012).  
Benzodiazepines were believed to be effective in treating anxiety conditions without 
many of the negative side effects associated with barbiturates (chronic fatigue, vision problems, 
mood swings, addiction and dependence). Indications for benzodiazepine use expanded over time 
to include management of illnesses such as epilepsy and as a myorelaxant (Neutel, 2005).   
By the 1970s, benzodiazepine prescribing had increased significantly, with diazepam 
becoming the most widely prescribed drug in Europe and the USA (Speaker, 1997). This 
prescribing trend continued throughout the 1970s. In 1977, benzodiazepines were the most 
prescribed drug globally, and in 1978, over 2.3 billion doses of diazepam were sold in the United 
States (Washton & Zweben, 2011; Dell’osso & Lader, 2013). This trend continued throughout 
the 1980s; in 1980, approximately 40 billion doses of benzodiazepines were consumed globally 
each day (Tyrer, 1980). Between 1969 and 1982, diazepam was the most prescribed drug in 
America (Dell’osso & Lader, 2013). 
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As the prevalence of this drug class increased, so did reports of adverse effects. As 
adverse effects, such as abuse liability, physical dependence and perceived addictiveness, were 
identified efforts were made to address them by changing prescribing guidelines (Rosenbaum, 
2005). In New York State, interventions were implemented to decrease the consumption of 
benzodiazepines in the late 1980s. When there was an attempt to decrease the prescribing of 
benzodiazepines, prescribers returned to the previous, more harmful alternative, barbiturates 
(Neutel, 2005; Rosenbaum, 2005). Concerns associated with benzodiazepine use from the 1980s 
continued into the 1990s. A study examining adults with anxiety disorders between 1989-1991 
concluded that approximately one third of adults did not receive any medication for treatment of 
their disorder, with approximately one third still not receiving medication in a 1996 follow-up 
(Salzman et al., 2001).  
During this time period, prescribers were hesitant to prescribe benzodiazepines for 
patients as it was perceived that these individuals were seeking a “high” or a “buzz” (Rosenbaum, 
2005). Due to this hesitancy, other treatments were used for conditions inappropriately. For 
example, for patients with Generalized Anxiety Disorder (GAD), there was an increase in 
antidepressant usage for those who did not have comorbid depression or another anxiety disorder 
(Rosenbaum, 2005). 
Throughout the 2000s, hesitancy to prescribe benzodiazepines lessened. Between 1996 
and 2013, the number of adults who filled a benzodiazepine prescription increased from 8.1 
million to 13.5 million (Bachhuber et al., 2016). During this period, some American adults were 
being prescribed more than one benzodiazepine resulting in an increase from 1.1 kg to 3.6 kg of 
lorazepam-equivalents per 100,000 adults (National Institute on Drug Abuse, 2018). 
Benzodiazepine prescribing continued to increase throughout the 2000s. For example, between 
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2009 and 2016, the total number of benzodiazepines dispensed increased by 226% in the United 
States (U.S Drug Enforcement Administration [DEA], 2016).  
In recent years, benzodiazepines have been used by adolescents and young adults as a 
recreational substance, primarily alprazolam (Xanax) and lorazepam (Ativan). As of 2013, 
misuse of benzodiazepines within the past month for young adults aged 12 and older, was 
estimated at 1.7 million people in the United States (SAMHSA, 2014). 
Due to increasing research highlighting the adverse effects of benzodiazepine usage, there 
was an attempt to create drugs with a wider therapeutic index (increased or same therapeutic 
effect with reduction of toxicity), resulting in the creation of ‘Z-drugs’. Zolpidem (Ambien) was 
introduced in the United States in 1992; however, as research increased on this class of drugs it 
was recognized, they were also associated with dependence and abuse (Victorri-Vigneau et al., 
2014; Nielsen., 2017). 
1.2 Benzodiazepine Prescribing 
In 1960, benzodiazepines were introduced to replace barbiturates and treat anxiety, stress 
and insomnia (Hollister, 1983). Benzodiazepines are separated into two categories: short acting 
and long acting, based upon the half-life of the drug. Decisions to use a short-acting or long-
acting benzodiazepine for an indication vary based upon the desired effects.  
Over time, the range of indications increased to include acute stress attacks and sleep 
disorders (National Institute on Drug Abuse, 2005), as well as post-traumatic stress disorder 
(Guina et al., 2015), schizophrenia and bipolar disorder (Brunette et al., 2003). 
Findings from several research groups concluded that inappropriate prescribing was 
prevalent, and benzodiazepines should typically be restricted to short-term usage (e.g., Swinson 
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et al., 2006). Cunningham et al. (2010) conducted a study in British Columbia between 1996 and 
2006, concluding that benzodiazepine usage increased in middle aged individuals over the 10-
year time frame studied (Cunningham et al., 2010). Similarly, a study comparing the prescribing 
patterns of benzodiazepines between Nova Scotia and Australia reported that the rate of 
prescribing was twice as high in Nova Scotia (Smith et al., 2008).  
Variations based upon geography have also been observed. Edelstein et al. (2014) 
determined that in less urban areas, 19.7% reported a psychotropic medication compared to 
14.2% in more urban areas. As well, those residing in rural Pennsylvania were 1.5 times as likely 
to use anxiolytics than those living in urban areas (Edelstein et al., 2014). This led to potential 
hypotheses such as individuals living in an urban area have increased access to health care 
resources.  
Benzodiazepines may be prescribed for anxiety disorders (including panic attacks), 
insomnia, seizure disorders and other indications approved by Health Canada (Health Canada, 
2019). However, prescribing of benzodiazepines for inappropriate indications and periods of time 
has been reported. Bartlett et al (2004) examined benzodiazepine use in Québec for a 5-year 
period, concluding that the average length of use of benzodiazepines among the elderly was 75 
days, substantially longer than the two to four-week recommended duration.  
When benzodiazepines are prescribed for durations longer than recommended, efficacy 
reduces over time and the risk of an adverse effect increases. Seniors are at an increased risk due 
to age-related changes in drug pharmacokinetics and pharmacodynamics resulting in an increased 
risk for drug toxicity (Handler et al., 2006).  
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Despite recommendations that benzodiazepine (BZD) prescribing should be limited to 
two to four weeks, research has shown that in some cases, BZDs are used for weeks, months or 
even years (Barnas et al., 1991; Ishigooka et al., 1998; Egan et al., 2000; Neutel et al., 2003).  
It is important that prescribers re-evaluate patients’ drug usage to ensure that prescriptions 
are within the established guidelines to mitigate the potential for abuse and adverse events. There 
have been reports that women are more likely to receive a benzodiazepine for non-medical 
reasons such as coping with stress and grief or adjusting to childbirth and menopause (British 
Columbia Ministry of Health, 2008). 
As the body of literature increased on adverse effects and prevalence of inappropriate 
prescribing, medical associations and governing bodies began to issue guidelines for appropriate 
prescribing and necessary precautions that should be taken when prescribing them. Globally, one 
such public health agency is the World Health Organization which published a document 
detailing precautions for benzodiazepine prescribing (WHO, 1996). Various countries have also 
issued guideline (at various points in time) for benzodiazepine prescribing, in an attempt to 
reduce inappropriate prescriptions. In Canada, provincial medical associations have issued 
guidelines to address the overprescribing of benzodiazepines (Newfoundland & Labrador 
Pharmacy Board, 2019). 
Other initiatives have been created that focus on reducing the prescribing of harmful 
medications, benzodiazepines among them. One such initiative is the Canadian Deprescribing 
Network, which focuses on knowledge translation through the creation of algorithms that can be 
used to stop the use of certain medication, including benzodiazepines, or to reduce the dosage 
safely (Canadian Deprescribing Network, 2017). Other approaches to reduce the overprescribing 
of medication, including benzodiazepines, are national campaigns such as Choosing Wisely 
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Canada and drug recovery initiatives (Government of Canada, 2014; Choosing Wisely Canada, 
2017).  
1.3 Polydrug Use  
Polypharmacy, the prescription of multiple medications concurrently, can be an issue 
across all medications, including benzodiazepines. When certain substances are ingested 
concurrently, the results can be harmful. Specifically, when benzodiazepines are combined with 
substances that act upon the central nervous system, such as opioids and alcohol, harmful effects 
(including death) can occur. Benzodiazepines are involved in more than 30 percent of overdoses 
involving opioids (National Institute on Drug Abuse, 2018). Both drug classes sedate users and 
suppress breathing, which is often the cause of overdose fatalities (National Institute on Drug 
Abuse, 2018). 
Sun et al. (2017) examined the concurrent use of benzodiazepines and opioids between 
2001 and 2013, with concurrent usage rising from 9 percent to 17 percent, respectively. One 
study comparing the overdose death rates between individuals receiving opioids and 
benzodiazepines concurrently and those receiving opioids only; the authors concluded that the 
death rate was 10 times higher in the population receiving both medications (Dasgupta et al., 
2016). Due to the risk of fatality when opioids and benzodiazepines are ingested concurrently, the 
United States Food and Drug Administration issued black box warnings on both classes of 
medication to highlight the extreme risk.  
It is projected that there will be 700,400 opioid overdose deaths between 2016 and 2025 
in the United States alone (Chen et al., 2019). Benzodiazepines were estimated to be involved in 
31% of opioid overdoses in 2011 (Jones et al., 2015). It is important to reduce inappropriate 
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prescribing of benzodiazepines, not only because of their adverse effects generally, but 
specifically to aid in reducing opioid overdoses and the chance of interactions with other 
medications. 
In recent years, benzodiazepines have been used by adolescents and young adults for 
recreational use, referred to as “Xans” in popular culture. As a result, drug diversion has become 
an increasing area of concern for adolescents and young adults (RCMP, 2010).  
 When benzodiazepines are consumed recreationally, alcohol is typically consumed 
concurrently. As noted, misuse of benzodiazepines combined with alcohol can be especially 
dangerous as both suppress the central nervous system (Jones et al., 2014). Combination of these 
two substances is of major concern for young adults; those between 18 and 25 have the highest 
prevalence of benzodiazepine misuse in the United States (SAMHSA, 2014). Kurtz et al. (2016) 
examined young adults in Miami involved in the ‘club scene’, concluding that 87.4% of the study 
sample had misused benzodiazepines. 
While polysubstance use is of concern, such as opioids and alcohol, polypharmacy is also 
of concern and typically affects the senior population due in part to the likelihood of being 
prescribed medications for comorbidities. A study examining polypharmacy in adults over 65 
years of age determined that 72.9 percent of the population was exposed to five drugs or more, 
while 28.4 percent of participants took 10 drugs or more (Blanco-Reina et al., 2016).  
When consuming multiple medications, there can be harmful drug-drug interactions 
amongst the drugs; however, for benzodiazepines, there is an added concern of patients being 
prescribed more than one benzodiazepine concurrently. Patients that are prescribed multiple 
benzodiazepines are at an increased risk for adverse effects due to the medications competing for 
the same receptor.  
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Drug diversion, the transfer of a legally prescribed substance from the individual to 
another for illicit use, is of particular concern. Prescription drugs are commonly passed on by, 
taken from or shared amongst friends and family members (Public Safety Canada, 2011b; Florida 
Office of the Attorney General, 2012; Wisconsin State Council on Alcohol and Other Drug 
Abuse, 2012). A 2009 report by the Royal Canadian Mounted police determined that 
benzodiazepines were one of the top diverted controlled prescription drugs across Canada that 
year (RCMP, 2010). Furthermore, the report concluded that most prescription drugs were 
obtained through legitimate domestic sources (RCMP, 2010). A 2011 Ontario Student Drug Use 
and Health Survey reported 67% of youth who used an opioid pain reliever non-medically in the 
past year, had obtained the drugs from an individual in the same household (Boak et al., 2017). 
Those using prescription medication for non-medical purposes may not be aware of the potential 
adverse effects or potential drug-drug interactions. 
Adolescents consuming benzodiazepines recreationally have the potential for an adverse 
effect due to three potential avenues: benzodiazepine use solely, the combination of 
benzodiazepines, and recreational substances such as alcohol or polypharmacy. The first two 
avenues have been previously discussed; however, the third is equally important. One of the 
issues with the consumption of benzodiazepines recreationally is the potential drug-drug 
interaction if the consumer is currently using another medication. 
When benzodiazepines are combined with alcohol, the result can be harmful. It is 
important to educate the public on proper use of prescription medication and to inform patients, 
not least to encourage informed decisions, about medication use. In 2017, approximately 375,000 
kids had taken a prescription medication not prescribed to them (Drug Free Kids Canada, 2017). 
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Among the most commonly abused prescription drug medications in this group are 
benzodiazepines (DFK, 2017). 
1.4 Adverse Effects of Benzodiazepines 
 Long-term usage of benzodiazepines has been linked to adverse effects: some are 
reversible while others are not. Dependence and tolerance are the most commonly reported 
adverse effects, however there is potential for more harmful adverse effects such as an increased 
risk of Alzheimer’s disease (Billioti de Gage et al., 2014) and hip fractures (Bartlett et al., 2009). 
Research focused on the adverse effects related to benzodiazepine usage have typically 
focused on populations of seniors. Some reasons why seniors are often studied for 
benzodiazepine usage include the physiological changes that occur as humans age and the 
accessibility to prescribed medication for those in a long-term care facility.  
 As people age, physiological changes occur, affecting the pharmacokinetics of drug 
metabolism resulting in increased sensitivity to BZDs and a decreased ability to metabolize 
certain medications in seniors (American Geriatrics Society, 2015). This decreased ability to 
metabolize certain medications can result in an increased susceptibility to adverse effects in 
seniors. While adverse effects are evident across all ages, seniors are particularly at increased risk 
for hip fractures, Alzheimer’s disease and others.  
While seniors are an important population in which to study the adverse effects of 
benzodiazepine use, they are not the only at-risk population. These effects occur in all adults, 
especially in those using benzodiazepines for long periods.  
 Common adverse effects include dependence, tolerance, withdrawal, confusion, 
drowsiness, memory loss and slurred speech (Neutel, 2005; Health Canada, 2019). Severe 
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adverse effects are related to benzodiazepine long-term usage including an increased risk of hip 
fractures in the elderly, cognitive decline, unwanted sedation, a reduction in coordination, a 
potential increased risk of Alzheimer’s disease and risk of automobile accidents (Ray et al., 1987; 
Salzman, 1993; Gales and Menard, 1995; Neutel, 1995; Neutel et al., 1996; Rickels et al., 1999; 
Neutel et al. 2002; Lenze et al., 2003; Kallin et al., 2004).  
 Adverse effects due to the consumption of benzodiazepines are of concern on their own, 
however polysubstance use with benzodiazepines can substantially increase the risk. A 
commonly reported effect is dependency as a result of benzodiazepine usage, which occurs when 
prescribed for greater than the recommended two to four-week period (Greenblatt and Shader, 
1978). Dependence can refer to either the physical or psychological, such as cravings, 
dependency that occurs from extended use. Development of dependence is related to the length of 
the prescription but can also differ based upon the classification of the benzodiazepine that is 
prescribed. Short acting benzodiazepines such as lorazepam (Ativan) take less time to develop 
dependence compared to long-acting benzodiazepines (Nelson and Chouinard, 1999). 
Another common adverse effect that is often associated with dependence is tolerance 
which results in an increased dose being required. By increasing the dose, the risk of an adverse 
effects is also increased (Greenblatt and Shader, 1978). Long-term usage of benzodiazepines can 
result in dependency and tolerance; however, withdrawal can also occur after long-term usage.  
While tolerance can be developed by consuming benzodiazepines for longer than the 
recommended time, Rickels & Schweizer (1998) reported that one third of patients were unable 
to discontinue therapy.  
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1.5 Study Objectives 
 Risks of inappropriate benzodiazepine prescribing are well documented; however, 
research has predominantly focused on prescribing patterns in those aged 65 years and older. Far 
less research has focused on younger and middle-aged adults. Due to the island of 
Newfoundland’s unique geography, it is important to examine the prescribing patterns in rural 
versus urban areas since there is little research focusing on geographic variation in prescribing 
patterns. Newfoundland’s unique geography includes many rural and remote communities, so 
these differences might be particularly important locally. This thesis will address that gap in the 
literature, as well as explore current benzodiazepine prescribing practices in comparison to 
recommended guidelines.   
This thesis will explore the similarities and differences between rural and urban 
benzodiazepine usage, as well as the prescribing patterns of benzodiazepines for all adults, not 
just seniors, compared to the recommended guidelines. It also utilizes a longer time period than 
many studies.   
 The primary research question for this study is: What are the similarities and differences 
between rural and urban benzodiazepine prescribing in Newfoundland and Labrador over a ten-
year period from 2007 to 2016? When addressing the current benzodiazepine prescribing 
patterns, it is important to assess current prescribing patterns and previous patterns, allowing for 
comparisons over time.   
These thesis objectives will be accomplished by examining benzodiazepine prescribing 
patterns for all adults aged at least 18 years of age in Newfoundland and Labrador, using data 
from the Newfoundland and Labrador Centre for Health Information from 2007 to 2016. Patterns 
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will be assessed based on geographic location (rural vs. urban) and stratified by prescriber 
specialty (general practitioners and specialists), sex (females vs males) and age range (18-24, 25-













































Chapter 2: Literature Review 
2.1 Introduction 
 
Benzodiazepines (BZDs), were introduced in 1960 to replace barbiturates as an 
anxiolytic. They were initially believed to be effective in treating conditions with minimal side 
effects compared to barbiturates. Initially introduced to treat anxiety and insomnia, the range of 
indications increased to include acute stress attacks and sleep disorders (National Institute on 
Drug Abuse, 2005), as well as post-traumatic stress disorder (Guina et al., 2015), epilepsy, 
muscle tension (Neutel, 2005), schizophrenia and bipolar disorder (Brunette et al., 2003).  
Research on the association between adverse effects and benzodiazepine usage continued, 
with reporting of adverse effects documented across numerous research studies, showing 
increased severity and frequency. Dependence and tolerance are commonly reported by long-
term users, however there is potential for more harmful adverse effects such as an increased risk 
of Alzheimer’s disease (Billioti de Gage et al., 2014) and hip fractures (Bartlett et al., 2009). 
Other severe adverse effects include cognitive decline, unwanted sedation, a reduction in 
coordination, and risk of automobile accidents (Ray et al., 1987; Salzman, 1993; Gales and 
Menard, 1995; Neutel, 1995; Neutel et al., 1996; Rickels et al., 1999; Neutel et al. 2002; Lenze et 
al., 2003; Kallin et al., 2004). 
In response to these reported adverse effects, several research groups concluded that 
inappropriate prescribing was prevalent, and BZDs should typically be restricted to short-term 
usage (Swinson et al., 2006). Despite recommendations that benzodiazepine (BZD) prescribing 
should be limited to two to four weeks,  research has shown that in some cases, BZDs are used 
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for many weeks, months or even years (Barnas et al., 1991; Ishigooka et al., 1998; Egan et al., 
2000; Neutel et al., 2003).  
Benzodiazepines will be discussed in the following sections, focusing on the 
epidemiology, prescribing patterns, inappropriate use and adverse effects associated with their 
use. 
2.2 Epidemiology of Benzodiazepines 
2.2.1 Global Epidemiology of Benzodiazepines 
Benzodiazepines (BZDs) are used globally to treat various indications, resulting in 
prescribing pattern variations by region. In 2008, usage varied amongst several European 
countries, varying from 5.8% to 16.3% (Huerta et al., 2016). Some countries have attempted to 
address this issue through the implementation of guidelines and providing a recommended 
duration of use. In many countries, benzodiazepines continue to be overprescribed.  
Kapil et al. (2014) estimated that 26.1% of the UK adult population had ever taken a BZD 
or Z-drug. Another study conducted in the UK, examining 1391 patients’ BZD prescriptions 
between 1991 and 2009, concluded that prescriptions were considered appropriate in only one-
third of cases (Dell’osso & Lader., 2011). Within Europe, prescribing differs by country. Hughes 
et al. (2016) examined the proportion of patients prescribed a benzodiazepine at least once 
between 2007 and 2015 in Scotland. During this time, the proportions decreased: 83.8% (n = 
109) in 2007, 70.5% (n = 122) in 2011, and 51.7% (n = 138) in 2015; however, there was an 
increase in the proportion of those prescribed a nonbenzodiazepine (“Z-drug”) from 30% (n = 39) 
in 2007, 46.2% (n = 80) in 2011, and 52.4% (n = 140) in 2015.  
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In France, based on a 2001 cross-sectional telephone survey, the prevalence of 
benzodiazepine usage was estimated to be 7.5% (Lagnaoui et al., 2004). Magrini et al. (1996) 
examined the prevalence of benzodiazepine use in an Italian adult population, determining that 
use in the past-week was 8.6%, with 5% in males and 11.8% in females. For those that were 
exposed to a benzodiazepine, 56% were chronic users, defined as daily for more than 6 months 
and 70.1% for those over the age of 65 (Magrini et al., 1996).  
Ohayon et al. (2002) examined a population aged 15 years or older consisting of 
participants from France, Germany, Italy, and the United Kingdom. Of the sample, 1.5% used 
hypnotics while 4.3% used an anxiolytic, concluding that anxiolytics are extensively prescribed 
in France and Italy. Another study examining 12,536 individuals 25 years of age or older in 
Sweden determined that 27.3% had been prescribed a benzodiazepine for 1-90 days, as well as a 
prescription of 90 - 270 days after first clinical diagnosis of depression, anxiety and/or insomnia 
(Sjöstedt et al., 2017). In Norway, anxiolytic and hypnotic sales decreased throughout the 1990s, 
but then increased annually by 3-6% (Grytten., 1998; Rønning., 2003). Based upon official sale 
statistics in 2000, approximately 5% of the Norwegian population used anxiolytics or hypnotics 
daily (Rønning., 2003; NOMESCO., 2003).  
Benzodiazepine usage continues to be of concern in Europe, similar to Middle Eastern 
Countries. Patel et al. (2013) examined the prevalence of benzodiazepine use in Pakistan: 
amongst 355 individuals, 129 (36%) reported benzodiazepine use currently. Among those taking 
benzodiazepines, 67% were taking them daily, with a mean duration of use of 93.07±203 weeks 
(Patel et al., 2013). Patel et al. (2008) determined that benzodiazepines are also the most common 
form of deliberate self-harm in Pakistan, observed in women more than men.  
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Raoof et al. (2008) reported that 30.4% of the study sample had used a benzodiazepine at 
one point in life, with 42.4% using them for more than 12 months; 36.5% were warned about the 
long-term addiction possibility associated with benzodiazepine usage. The most common 
indication for which a benzodiazepine was prescribed was sleep disturbance, differing from the 
most common indication for BZDs in North America. A study conducted by Khawaja et al. 
(2005) determined the point prevalence of benzodiazepine usage at a tertiary care university 
hospital in Pakistan to be 21.2%.  
In Thailand, in 2007, 1.6% of the general population indicated they had misused 
anxiolytics or hypnotics at some point during their life (Assanangkornchair et al., 2010). 
Examining usage in Taiwan between 1997 and 2004, Chien et al. (2007) reported the prevalence 
of anxiolytic-hypnotic use increased from 3.0% to 7.3% respectively. Fang et al. (2009) 
determined that the annual prevalence in 2000 was higher at 18.6% based on a sample of 187,000 
individuals. Examining benzodiazepine usage in Lebanon, Ramadan et al. (2016) determined that 
33% had experienced side effects and 40% had been taking a benzodiazepine for more than one 
year.  
Benzodiazepine prescribing in Japan was examined by Nakao et al. (2009), reporting 
19.9% of inpatients being prescribed a benzodiazepine. Prescribing by department was 
determined to be highest in neurology (35.8%) and cardiac surgery (35.8) (Nakao et al., 2009). 
These prescribing patterns in Japan vary from the predominant use of benzodiazepines in North 
America, where BZDs are primarily prescribed for anxiety and insomnia.  
In 2001, 90 million benzodiazepine prescriptions were written for mood and anxiety 
disorders with 31 million prescriptions written for alprazolam alone in the United States (Stahl., 
2002). While it was anticipated that this rate of prescribing would decrease, 85 million 
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benzodiazepine prescriptions were written for the same indications in the United States in 2007 
(Rickels, 2013). In 2008, the annual prevalence of benzodiazepines was estimated at 5.2% of the 
US population with long-term usage increasing from 14.7% (18-35 years) to 31.4% (65-80 years) 
as age increased (Olfson et al., 2015). Estimates from SAMHSA (2011) determined that 
approximately 272,000 emergency department visits involved nonmedical use of a 
benzodiazepine in the United States in 2008, with 40% of those visits also involving alcohol. In 
2011, this increased to approximately 426,000 visits, with 24.2% involving alcohol (SAMHSA., 
2013).  
The frequency of benzodiazepines and similar sedative-hypnotics has been reported to be 
approximately 3.4% in Canada, based on a 2006 study (Kassam et al., 2006). In summary, 
research clearly demonstrates that inappropriate benzodiazepine prescribing is evident globally. 
Our study focused on prescribing and usage in the province of Newfoundland and Labrador over 











2.2.2 Epidemiology of Benzodiazepines in the Canadian Provinces 
 
Table 2.1. Benzodiazepine Usage in Canadian Provinces (2017)1  
 
Province2 Defined Daily Doses per 1,000 
population for BZRA3 
Newfoundland and Labrador 25,722 
Nova Scotia 17,692 
Prince Edward Island 21,906 






British Columbia 9,656 
Canada 12,248 
       1Pan-Canadian Trends in the Prescribing of Opioids and Benzodiazepines, 2012 to     
                      2017. Canadian Institute for Health Information. Available at:     
                      https://www.cihi.ca/sites/default/files/document/opioid-prescribing-june2018-en-   
                      web.pdf 
           2Not including Canadian Territories 
        3BZRA: Benzodiazepine and benzodiazepine-related drugs 
 
In 2004, the annual prevalence of BZD use was estimated at 4% of the Canadian 
population (Olfson et al., 2015). Potentially inappropriate prescriptions in Canada in 2013, filled 
by adults 65 years of age and older, cost approximately 419 million dollars (Morgan et al., 2016).  
Hogan et al. (2003) reported benzodiazepine use across Canada, with use being highest in 
Quebec (35.9%) and lowest in the Prairies (18.2%) and Atlantic Canada (6.6%).  
In British Columbia, 4.9% of the population filled a benzodiazepine prescription less than 
100 days in total supply, while another 3.5% filled a BZD prescription for more than 100 days in 
total supply in 2006 (Cunningham et al., 2010). BZD users in this population were typically 
women, which accounted for two-thirds of the prescriptions, and older with nearly half over 65 
and more than a quarter 75 or older (Cunningham et al., 2010). The prevalence of benzodiazepine 
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usage in British Columbia increased from 7.8% in 1996 to 8.4% in 2006 (Cunningham et al., 
2010).  
In Alberta, 10% of the population (over 10 years of age) was dispensed a BZD or Z-drug 
in 2015 (Weir et al., 2018). Per 100 patients, one consumed a benzodiazepine from 10-19 years 
of age, increasing to 14 per 100 for 50-59 and 30 for 90 years and older (Weir et al., 2018). 
Differences in sex were also observed: 13% of females were dispensed a BZRA (benzodiazepines 
and z-drugs) in 2015, compared to 8% of males (Weir et al., 2018). 71% of patients had a 
maximum period of usage longer than 30 days (mean = 90, SD = 95) on average with the number 
of distinct prescribers (mean = 1.5, SD = 1.0) (Weir et al., 2018).  
Quinn et al. (1992) reported benzodiazepine use in a Saskatchewan population to be 
5.5%, with an average of 4.7 prescriptions per person and 255 per 1000 people prescribed a BZD.  
Alessi-Severinin et al. (2013) examined the change in BZRA use in adults 65 years of age 
or older in Manitoba. Incident of use of a BZRA in 1998 was 13.14 users per 1000 persons and 
13.66 users per 1000 persons in 2009 (Alessi-Severinin et al., 2013). The prevalence of use of a 
BZRA was 108.6 per 1000 persons in 1997/98 and 109.1 / 1000 persons in 2008/2009 (Alessi-
Severinin et al., 2013). 
Tu et al. (2001) reported the prevalence of people dispensed a benzodiazepine in Ontario 
decreased from 25.1% in 1993 to 22.5% in 1998 for the study population (age 65 and older). 
Prevalence of BZD usage increased for all six years studied when stratified by age, 
approximately 20% for the 65-69 age group and 30% for greater than 85 years of age (Tu et al., 
2001). 
Préville et al. (2012) examined benzodiazepine usage in Quebec, concluding that 32% of 
survey respondents had a mean daily dose of 6.1 milligrams of equivalent diazepam for an 
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average of 205 days per year. Additionally, 48% of BZD users had received a potentially 
inappropriate benzodiazepine prescription within the previous year. Furthermore, 23% of BZD 
users had received at least one prescription of a medication concurrent with a BZD that had the 
potential for a serious drug-drug interaction. A 1977 study examining benzodiazepine usage in 
Quebec reported that in a 1977 family medicine center, diazepam was the second most commonly 
prescribed drug (Rosser, 1980). Mariner et al. (1982) reported that diazepam was the second most 
commonly used medication, after Aspirin, among urban women in Quebec. 
A recent study of benzodiazepine use among older adults in Quebec, reported 24.3% of 
benzodiazepine users received long-acting drugs (Olfson et al., 2014). In British Columbia, an 
estimated 8.4% of the population used a benzodiazepine in 2006, with 3.5% filling 
benzodiazepine prescriptions in excess of 100 days of supply (Cunningham et al., 2010).  
Black et al. (2018) reported benzodiazepine usage across provinces in Canada for those 
65 years of age or older, reporting New Brunswick having the highest prescribing (43,989 units). 
In 2012, there were 25.5 million prescriptions of BZDs and Z-drugs in Canada (Canadian 
Institute for Health Information, 2018); Newfoundland and Labrador had the highest defined 
daily doses dispensed of BZDs.  
2.2.3 Benzodiazepine Usage in Newfoundland and Labrador 
 In 2017, in Newfoundland and Labrador, the defined daily doses dispensed of BZDs per 
1,000 persons was 15,932, ranking highest amongst the Canadian provinces (Canadian Institute 
for Health Information, 2018). When analyzing benzodiazepine and Z-drugs (BZRA) combined, 
the defined daily doses dispensed per 1,000 persons was 25,722, a 0.5% increase from the 
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previous year (Canadian Institute for Health Information, 2018). Newfoundland was the only 
province with an increase between 2016 and 2017 for BZRAs.  
A significant proportion of the Newfoundland and Labrador population comprises 
seniors: 19.4% are over the age of 65, compared to 16.9% nationally (Statistics Canada, 2016). 
However, with increasing drug diversion and young adults using benzodiazepines illicitly, it is 
also important to examine usage across all age groups. 
Further, Newfoundland's unique geography and dispersion of communities warrants a 
focused exploration of benzodiazepine usage in urban and rural communities. There are 
differences in these regions in access to health care services and providers, as well as other 
variables that may impact prescribing patterns. Finally, it is worthwhile to examine prescribing 
trends over time.  
2.2.4 Benzodiazepine Usage by Age  
 
Seniors are a large benzodiazepine user group in the general population and are likely to 
receive an inappropriate prescription. For example, Bergman et al. (2007) examined nursing 
home residents aged 65 years and older, concluding that over 70% had one or more potentially 
inappropriate prescriptions. Combined with the potential for severe adverse effects, seniors are 
often researched regarding benzodiazepine usage. It is important to focus on seniors since 
physiological changes occur with aging, affecting the metabolism of pharmacological 
interventions, including benzodiazepines. Seniors are also more susceptible to adverse effects as 
some have the potential for a more negative outcome. Hip fractures are one adverse effect that 
can occur with long-term benzodiazepine usage which requires surgery. Seniors have an 
increased risk of mortality due to surgical complications than young adults. Due to seniors being 
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more susceptible to adverse effects, such as hip fractures due to falls, benzodiazepine prescribing 
is often examined in this population (Wagner et al., 2004). However, seniors are not the only 
population that use benzodiazepines and research has also examined BZD usage in younger 
populations. 
Between 2006 and 2013, the prevalence rate of benzodiazepine usage amongst those aged 
0 - 24 years in Sweden increased from 0.81 per 100 inhabitants to 0.99 per 100 inhabitants, based 
on 117,739 individuals who had filled at least one benzodiazepine prescription (Sidorchuk et al., 
2018). In a Canadian population, 32.3% of short-term users were aged 18-44 with 42% in the 45-
64 category (Weymann et al., 2017). Benzodiazepine prescribing has been researched in minors, 
with an increase of 10.2% between 2009 and 2012 in an Irish population; with 15% prescribed a 
benzodiazepine for longer than four weeks (Murphy et al., 2015). 
Young adults are also more likely to misuse prescription medication recreationally than 
seniors (those 65 years of age and older). Among a nightclub-going sample, most frequently 
young adults, prevalence of use approaches 65%–90% lifetime (Grov et al., 2009; Kelly and 
Parsons 2007; Kurtz et al. 2013). A study examining prevalence of benzodiazepine usage 
conducted using a sample of drug-using young adults 18–29 years of age recruited at clubs found 
a prevalence of 47.1% recent (past four months) usage (Kelly and Parsons 2007). 
In the United States, Olfson et al. (2015) reported approximately 5.2% of US adults 
between 18 and 80 years of age were prescribed a benzodiazepine. Additionally, benzodiazepine 
use increased between age groups from 2.6% (18-35 years) to 5.4% (36-50 years) to 7.4% (51-64 
years) to 8.7% (65-80 years). 
Lifetime anxiety disorder prevalence is also increasing, with an average onset age for 
diagnosis of panic disorder, major depression and generalized anxiety disorder of 23 - 30 years 
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old (Kessler et al., 2012). Smartphones are ubiquitous in society, contributing to the increase in 
rates of anxiety diagnoses. Furthermore, excessive smartphone usage can result in disturbed sleep 
patterns which may lead to a prescriber using a benzodiazepine for the treatment of insomnia in 
young adults (Khan et al., 2015). 
Panic disorder, major depression, and generalized anxiety disorder diagnoses often result 
in a benzodiazepine prescription for the indication. In young adults, excessive prescriptions can 
lead to drug diversion. Drug diversion has become a major issue in adolescents and young adults, 
through the popularization of consuming prescription medication recreationally via pop culture.  
Long-term benzodiazepine usage also increased with age from 14.7% (18-35 years) to 
31.4% (65-80 years) (Olfson et al., 2015). Neutel (2005) examined the differences between age 
groups, concluding that those aged 40-59 were 2.9 times more likely than the 20-39 group to use 
a BZD, and the 60+ demographic, 5.8 times more likely.  
With the emergence of smartphone technology, rates of depression and anxiety have 
increased. A study involving 210 Korean female students concluded that 30.5% had a high risk of 
smartphone addiction (Lee et al., 2015). Matar Boumosleh and Jaalouk (2017) examined a 
population of Lebanese university students of 688 undergraduate students concluding that 26.5% 
felt anxious. Benzodiazepines are prescribed for anxiety; however, inappropriate lengths of usage 
need to be examined in younger populations (less than 30 years of age).   
2.3 Clinical Use of Benzodiazepines 
 
Benzodiazepines act upon the gamma-aminobutyric acid (GABA) receptors suppressing 
the central nervous system effects, resulting in anxiolytic, sedative, hypnotic, skeletal muscle 
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relaxant and antiepileptic effects (McEvoy et al., 2002; Barker et al., 2004). When 
benzodiazepines were initially introduced, they were intended to treat anxiety and insomnia 
(CPS, 2003; Alessi-Severini, S. et al., 2014; Katzman, M. et al, 2014). Indications for which 
benzodiazepines are used has increased to include nervousness and sleep problems (Curran, 
1991; Barbee, 1993; King, 1994; Kirby et al., 1999; Jorm et al., 2000; Sonnenberg et al., 2012). 
BZDs are also used for the treatment of psychotic states, depression, social phobia (including 
social anxiety disorder), obsessive-compulsive disorder, drug withdrawal and the adverse effects 
caused by antidepressants and antipsychotics (Pollack, 1993; Barker et al., 2004).  
Benzodiazepines may also be prescribed as a myorelaxant and post-surgery for brief 
periods (Neutel, C., 2005) or for the management of post-traumatic stress disorder, schizophrenia, 
bipolar disorder, tremors in multiple sclerosis patients and epilepsy (Brunette et al., 2003; Mehdi, 
2012; Guina et al., 2015; Meador et al., 2015).  
 Health Canada allows for the prescribing of benzodiazepines for the following 
indications: anxiety, insomnia, alcohol withdrawal, muscle spasms, and an anesthetic before 
surgery. Commonly marketed benzodiazepines include alprazolam (Xanax), clonazepam 
(Klonopin), diazepam (Valium), lorazepam (Ativan), flunitrazepam (Rohypnol), 
chlordiazepoxide (Librium), and midazolam (Versed). Z-drugs, commonly referred to as BZD 
clones, are a drug class similar to BZDs and often used to treat insomnia and anxiety. Commonly 
marketed Z-drugs include zopiclone (Imovane), eszopiclone (Lunesta) and zolpidem (Ambien). 
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2.4 Inappropriate Use 
Globally, benzodiazepines are one of the most commonly prescribed medications and one 
of the most inappropriately prescribed medications. Inappropriate prescribing can be defined by 
inappropriate indication, dosage, strength, duration and / or multiple benzodiazepines prescribed 
concurrently. Inappropriate usage can also include patients misusing benzodiazepines or by using 
the medication concurrently with known medications that interact with BZDs. Inappropriate use 
will be further discussed in this section.  
2.4.1 Inappropriate Prescribing (Duration, Strength, Multiple BZDs, Indications) 
 Inappropriate use has multiple definitions. This section will focus on inappropriate 
duration, strength and the prescription of multiple benzodiazepines concurrently; however, it is 
likely benzodiazepines are also used for other inappropriate indications. 
Guidelines recommend that benzodiazepine usage be restricted to two to four weeks; 
however, prescribers do not always adhere to these guidelines. Long-term benzodiazepine 
prescriptions, defined as greater than 30 days, for any indication contradicts various guidelines 
(Copperstock & Hill, 1982; APA, 1990; WHO, 1996; Katzman et al., 2014). Usage varies by 
countries, with indications that between 0.5% and 5.8% of the adult population use 
benzodiazepines for 1 year or longer (Barker et al., 2004). 
Sonnenberg et al. (2012) reported on benzodiazepine usage in a Dutch population aged 55 
– 64 years of age; long-term usage was 70% of total BZD usage in 1992 and 80% in 2002. A 
Quebec study noted that benzodiazepines were used for longer than 12 weeks in 88.4% of the 
study sample (Bernard et al., 2018). A systematic review including 13 studies reported usage 
ranging from 1 to 34 years with a mean of 9.9 years (Barker et al., 2004).  
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Olfson et al. (2015) reported the proportion of benzodiazepine use that was long-term 
increased with age: for 18-35 years old, 14.7% was long-term while it was 31.4% for those 65-80 
years old. Variables associated with long-term benzodiazepine usage include age, sex and low 
socioeconomic status. Sundquist et al. (2017) reported that individuals aged 85 years and older 
were three times as likely to be prescribed a benzodiazepine than those aged 25 - 44 with 
clinically diagnosed depression, anxiety and / or insomnia.  
In the elderly, inappropriate prescribing rates (based upon different definitions of an 
inappropriate prescription) have been reported to be between 14% and 23% of all prescriptions 
(Brekke et al., 2008). 20-25% of inappropriate prescriptions in the elderly are related to 
benzodiazepine prescriptions (Tannenbaum et al., 2014). Fride Tvete et al. (2015) reported 
women having a lower risk than men for excessive use, and those with low household income 
being associated with a high risk for excessive benzodiazepine use.  
Inappropriate prescribing may refer to the strength of the benzodiazepine prescribed. As 
usage is continued, tolerance develops, resulting in the prescribing of an increased strength being 
provided to the patient. Continual increase of strength is not an effective or safe method to treat 
the patient (Katzman et al., 2014). 
Specifically, in seniors, this can be problematic due to pharmacological changes that 
occur as humans age resulting in an increased duration of the effects of benzodiazepines on the 
elderly. A study conducted in Sweden analyzed long-term benzodiazepine usage rates based upon 
participants from multiple research centers located throughout Sweden, concluding that older age 





2.4.2 Polydrug / Polysubstance Use 
Benzodiazepine usage greater than recommended guidelines, or greater than 30 days, can 
result in harmful effects. While inappropriate prescribing results in hazardous effects on patients, 
so can polysubstance use. Benzodiazepines are overprescribed in middle-aged individuals and 
more frequently in those 65 years of age and older. In 2016, 1 in 4 Canadian seniors were 
prescribed 10+ drug classes (CIHI, 2018).  Use of other medications is a strong predictor for 
initiating BZD usage (OR: 1.85) (Bartlett et al., 2009).  
 While BZD overprescribing is most prevalent in those aged 65 years and older, this 
population is also at risk for being prescribed a medication that has a drug interaction with a 
benzodiazepine. A study conducted by Ramadan et al. (2016) reported that 18.3% of those using 
benzodiazepines were taking drugs that should not be prescribed with BZDs. An example of this 
is in the treatment of generalized anxiety disorder, where benzodiazepines have been used in 
conjunction with an antidepressant (Louvet et al., 2015); in some of these cases, patients have 
difficulty discontinuing the BZD.  
A large study including 547, 709 residents of an Alberta population who received an 
opioid prescription found that 24% also received prescriptions for a BZRA (Sharma et al., 2019). 
Currently, there is an opioid epidemic in North America resulting in hospitalizations and death in 
some. Benzodiazepines, when consumed with opioids can result in fatality leading the Food and 
Drug Administration (FDA) to issue a black box warning that is required to be present on both 
medications. A concern about benzodiazepine usage is the impact that can occur as a result of 
consuming a benzodiazepine in combination with additional drugs. This consumption of various 
drugs can result in drug interactions which can have harmful effects. Benzodiazepines can also be 
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used recreationally by young adults, resulting in drug-drug interactions that are previously 
unknown.  
2.4.3 Misuse of Benzodiazepines  
Benzodiazepines are misused for multiple reasons such as to help sleep, to get high or for 
social reasons (Kapil et al., 2014). Data from the National Survey on Drug Use and Health 
(NSDUH) indicated that 9.8% of sedative/tranquilizer misusers met the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV) criteria for abuse and/or dependence (Becker, Fiellin, and 
Desai 2007). 
Similar to pharmaceutical opioids, a large proportion of the literature focused on 
problematic use addresses concerns with prescribing practices (Grossbard et al. 2014). There is a 
paucity of research on the epidemiology and health consequences of recreational BZD misuse 
among high-risk groups. Benzodiazepines can be misused, with some cases resulting in 
hospitalization, which can be classified into different categories. The resulting emergency room 
(ER) visits are typically classified into benzodiazepine ER visits due to medical use and those 
due to non-medical use. 
Based upon 1500 respondents, Kapil et al. (2014) reported the most common reasons to 
misuse benzodiazepines and Z-drugs were to help sleep (66.4%), cope with stress (37.1%) or to 
get high (31%). Of these respondents, 55.2% received the medications from healthcare 
professionals. This highlights the importance of reviewing prescribing guidelines and practice. 
One category is the misuse of benzodiazepines is due to incorrect dosage. This can occur 
from patients consuming more than the prescribed dosage, potentially due to a feeling of 
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tolerance when no tolerance is present. Another source of benzodiazepine misuse is consuming 
another individual's prescription which was not originally intended for them. 
Among suicide attempts by poisonings due to a substance, benzodiazepines are used for 
30% to 40% of attempts in western countries, with this increasing to 80% in Pakistan (Khawaja 
et al., 2006).  
Benzodiazepines are misused in a variety of ways. Through inappropriate prescribing, 
polydrug use and misuse, these can all lead to an individual experiencing adverse effects 
associated with benzodiazepines usage. Often the misuse of other substances, such as opioids, 
coincides with the misuse of benzodiazepines. Illicit drug use, such as opioids, has been reported 
to be used concurrently with benzodiazepine usage (Tucker et al., 2016). 
After reviewing some drug manufacturer information, it is important to discuss the 
indications for which benzodiazepines are intended compared to why they were prescribed. 
Healthcare providers need to be aware of this difference and that benzodiazepines were used to 
treat insomnia and as an anxiolytic initially.  
Benzodiazepines are prescribed primarily as an anxiolytic and for insomnia. It is 
important to differentiate between GAD and anxiety associated with the stresses of everyday life. 
This difference is specified in the drug monographs from pharmaceutical companies 
manufacturing benzodiazepines (Health Canada, 2019). Regardless, benzodiazepines are still 
prescribed – often inappropriately -for the stresses associated with everyday life. In the drug 
monograph, the length of use is also specified to be between two and four weeks. For example, 
the drug monograph for Ativan (lorazepam) states that long-term usage is not recommended 
(Wyeth, 2019). Even with these recommendations by the pharmaceutical companies, this is not 
necessarily a deterrent for prescribers or patients.  
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For clinical long-term use of benzodiazepines, it is important to examine continued 
benefit. Continued benefit refers to the benefit of the drug to the user as the drug is continued, 
such that if a drug is continued to be used, the positive effect remains (although this is often not 
the case with benzodiazepines). 
2.5 Adverse Effects 
 
Benzodiazepines were initially introduced as a safer alternative to barbiturates in the 
1960s. As described, prescriptions of benzodiazepines increased, with it becoming one of the 
most prescribed medications globally. As research began to examine the adverse effects 
associated with usage, the list of reported adverse effects grew to include hip fractures due to 
falls, dependence and cognitive impairment. These effects range from withdrawal symptoms to a 
potential increased risk of Alzheimer’s disease. This section will discuss the adverse effects 
associated with benzodiazepine usage. 
Examining benzodiazepine usage in Lebanon, Ramadan et al. (2016) reported that 33% 
had experienced side effects and 40% had been taking a benzodiazepine for more than one year. 
Glass et al. (2005) determined that adverse events were more common with sedatives than 
placebo.  
Due in part to the adverse effects associated with long-term benzodiazepine use, there 
were attempts to create an alternative drug that had similar therapeutic effects, but a lower 
possibility of adverse effects. As a result, Z-drugs were introduced to have the intended effect. As 
research increased on Z-drugs, however, it became apparent that adverse effects were similar to 
those of benzodiazepines. 
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2.5.1 Cognitive Decline, Unwanted Sedation, Reduced Motor Coordination 
Benzodiazepine usage, especially long-term usage, has been associated with a decline in 
cognitive function. A meta-analysis examining risks and benefits of sedative-hypnotics 
determined that cognitive adverse events are 4.78 times more common and adverse psychomotor 
events are 2.61 times more common in those using a sedative compared to a placebo (Glass et al., 
2005).  
Associations between dementia and benzodiazepine usage have been reported (Billioti de 
Gage et al., 2014; Gray et al., 2016; Islam et al., 2016). Billioti de Gage et al. (2014) analyzed the 
correlation between benzodiazepine use and the risk of Alzheimer’s disease. They reported an 
odds ratio of 1.51 associated with an increased risk of Alzheimer’s disease in those that used 
benzodiazepines. Notably, impairment can remain for months after the benzodiazepine is 
discontinued (Cunningham et al., 2010).  
While cognitive decline has been associated with benzodiazepine usage, decreased motor 
skills have also been reported. Psychomotor impairment can significantly impact driving 
performance. Daurat et al. (2013) examined the effects of lorazepam on driving, specifically lane 
departure, determining that under the influence of lorazepam, driving performance was worse 
than having a blood alcohol concentration above 0.05. A meta-analysis examining sedative-
hypnotics with the risks and benefits determined that cognitive adverse events are 4.78 times 
more common and adverse psychomotor events 2.61 times more common in those using a 
sedative compared to a placebo (Glass et al., 2005).  
While benzodiazepines have the potential to increase the risk of Alzheimer's disease, 
BZDs may also have negative health impacts on those who are already affected with Alzheimer's. 
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After discontinuation of the benzodiazepine, it is possible for the cognitive impairments to 
regress and in some cases, the individual may return to the same level of cognitive function that 
was previously experienced. Thus, while there has been research highlighting the increased risk 
of Alzheimer's disease from benzodiazepine consumption, it is important to also consider 
individuals who have dementia and are prescribed a benzodiazepine. 
2.5.2 Falls, Hip Fractures in the Elderly, Balance 
Falls are of significant concern in those aged 65 years and older: approximately 28-35% 
of those 65 years and older fall each year (Yu et al., 2017), and it is the second leading cause of 
accidental or unintentional death globally (WHO, 2018). Risk of falls is already high in this 
population and is further compounded by benzodiazepine usage, especially long-term usage.  
Ming and Zecevic (2018) conducted a systematic review including studies from differing 
countries and reported an increased risk of falling of 1.2 to 3.7 times for older adults when taking 
a benzodiazepine. Donnelly et al. (2017) conducted a systematic review examining the risk of hip 
fracture for those using benzodiazepines and Z-drugs, finding that both were significantly 
associated with an increased risk of hip fracture with a relative risk of 1.52 and 1.90, respectively.  
Research has demonstrated that benzodiazepine usage is associated with an increased risk 
of hip fractures, with this association also being present for short-term usage. Short term use of 
BZDs, defined as up to fourteen days since initial prescription, resulted in a 140% increased risk 
(compared to non-exposure); Z-drugs had an increased risk of 139% (Donnelly et al., 2017). Falls 
and hip fractures in the elderly have been widely reported; however, it was initially believed that 
the association was due to long-term use. However, Wagner et al. (2004) reported that hip 
fractures in the elderly are associated with benzodiazepines even after two weeks of use. 
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Psychomotor skills are impaired with long-term benzodiazepine usage which can 
contribute to the risk of a fall, but also impairs other motor skills such as driving. A 2010 study 
highlighted the importance of reduced balance from a single dose of a hypnotic medication, such 
as a benzodiazepine (Mets et al., 2010). 
Z-drugs were initially believed to have a reduced adverse effect profile while achieving 
similar hypnotic results clinically to BZDs. As research increased on Z-drugs, however, it 
became apparent that many of the adverse effects associated with benzodiazepine usage were 
similarly observed in Z-drug use. One of these adverse effects is the increased risk of falls and a 
hip fracture, and again, increased risks with long-term usage (Ackroyd-Stolarz et al., 2009; 
Bartlett et al., 2009; Bronskill et al., 2018). 
2.5.3 Tolerance, Withdrawal and Dependence 
People with benzodiazepine usage longer than 3-4 weeks are likely to develop withdrawal 
symptoms upon cessation (Petursson & Lader, 1981; Brett & Murnion., 2015). Dependence had 
previously been thought to be observed only in individuals using benzodiazepines for extended 
periods of above-normal therapeutic doses. However, research has demonstrated that even for 
benzodiazepines used at a normal therapeutic dose, physiological and pharmacological 
dependence can be observed when the medication is ceased (Barker et al., 2004).  
Benzodiazepines with a short half-life and high potency (such as alprazolam, lorazepam, 
and triazolam) increase the risk of dependence (Nelson & Chouinard, 1999). Dependence is most 
commonly discussed in the context of prescription drug use among individuals for which the 
medication is intended; however, it can also develop in those using the medication recreationally.  
(Kurtz et al., 2016).  
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2.5.4 Additional Adverse Effects 
Benzodiazepines have been associated with many adverse effects. Besides those 
previously discussed, other adverse effects have also been reported; including rebound seizures, 
rebound insomnia, mortality amongst those with chronic obstructive pulmonary disease (COPD), 
suicide risk, stroke, cardiovascular disease (CVD), mortality and pneumonia (Obiora et al., 2013;  
Airagnes et al., 2016; Kroll et al., 2016; Brandt & Leong, 2017; Donovan et al., 2019). In all, 
BZD usage has been associated with numerous and serious adverse effects.  
2.6 Burden on the Healthcare System 
Inappropriate benzodiazepine prescribing is not only harmful but can also significantly 
impact the healthcare system through both direct and indirect costs. In Canada, potentially 
inappropriate prescriptions filled by older adults cost an estimated 419 million dollars; in 
Newfoundland and Labrador, this cost was $128 per person aged 65 years or older (Morgan et al., 
2016).  
Indirect costs associated with benzodiazepine overprescribing include the time and burden 
on the healthcare system measured in increasing wait times due to adverse effects and costs 
associated with utilization of hospital equipment and personnel. For example, annual costs of hip 
fractures in the United States had an estimated cost of $10.3–15.2 billion dollars (Donnelly et al., 
2017). In the United Kingdom, this is estimated at 2 billion Great British Pounds (GBP) (NICE, 
2011). These costs are not solely due to benzodiazepine overprescribing: inappropriate 
prescriptions may lead to adverse effects, such as hip fractures, that place further burden on the 
healthcare system.  
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2.7 Study Objectives 
 Benzodiazepines are overprescribed; however, research has predominantly focused on 
prescribing patterns in those aged 65 years and older. It is important to examine the prescribing of 
benzodiazepines in all adults, not just seniors. 
While research has been conducted comparing rural and urban areas (Fourrier et al., 2001; 
Laganoui et al., 2004;  Alessi-Severinin et al., 2014; Mattos et al., 2016; Weymann et al., 2017; 
Agarwal et al., 2019; Sharma et al., 2019), there are limitations and no previous research could be 
found that has examined rural / urban benzodiazepine usage in Newfoundland and Labrador 
(NL). In 2016, NL had 519,716 residents with 311,356 dispersed across 269 towns (Statistics 
Canada, 2017). Due to this unique geography, it is important to examine prescribing patterns 
between rural and urban regions. In 2017, NL had the highest rate of benzodiazepine daily doses 
dispensed per 1,000 persons in Canada and was the only province with an increase between 2016 
and 2017 (CIHI, 2018). In light of the economic and social burden of BZDs and the documented 
increase of BDZ usage in NL, it is valuable to further explore prescribing and usage patterns in 
the province. 
The primary research question for this study is: What are the similarities and differences 
between rural and urban benzodiazepine prescribing patterns in Newfoundland and Labrador, 
among those 18 years of age or older, over ten years from 2007 to 2016? We hypothesized that 
there was a significant difference between rural and urban usage, with rural areas being 






























Chapter 3: Methodology 
3.1 Overview 
3.1.1 Study Design 
A retrospective cohort study utilizing secondary data was used to examine benzodiazepine 
prescribing patterns from 2007 to 2016. Data was collected for participants that received a 
benzodiazepine prescription living in Newfoundland (a subregion of Newfoundland and 
Labrador).  
 
Specifically, the cohort was from the Newfoundland and Labrador Prescription Drug 
Program (NLPDP). The NLPDP is a program that offers financial assistance for eligible 
prescriptions. It is responsible for covering individuals when other services will not; as such, it is 
a payor of last resort.  
Within the NLPDP there are five different programs: The Foundation Plan, 65Plus Plan, 
Access Plan, Assurance Plan and Select Needs Plan. Both the Foundation and Access Plan 
provide coverage for eligible prescriptions for those who receive income support benefits or are 
of low income. The 65Plus Plan is for individuals 65 years of age or older who received old age 
security benefits. The Assurance Plan covers medications in families where eligible drug costs 
exceed: 5% of net income for those who earn less than $40,000, 7.5% of net income for those 
who earn $40,000 to $75,000 or 10% of net income for those who earn $75,000 to $150,00. The 




Data from the NLPDP is extracted from an administrative dataset for applying 
reimbursement through this program by the Newfoundland and Labrador Centre for Health 
Information (NLCHI). Using data from this database, for those who were prescribed a 
benzodiazepine, rates of inappropriate prescription were determined and compared across a ten-
year period, from 2007 to 2017.   
3.1.2 Purpose of Study and Objectives 
Examining benzodiazepine usage among those, aged 18 years of age or older, living on 
the island of Newfoundland from 2007 to 2016, while comparing differences in usage between 
rural and urban areas, was the objective of this study. Using the NLPDP database, 
benzodiazepine prescribing, and usage were examined stratifying by age, sex and prescriber 
specialty. 
3.2 Definitions 
Benzodiazepine usage can be measured in a variety of ways. The sections below provide 
clarification of study definitions, measures and outcomes.  
3.2.1 Definition of Benzodiazepine Usage 
Benzodiazepine prescribing and benzodiazepine usage are different terms. For this study, 
it was assumed that the benzodiazepines which were prescribed were used by the patients for the 
indications that they were intended and for the intended duration. It is acknowledged that in 
reality this may not be the case. It is possible that a patient did not use the medication for the 
complete duration of the prescription. As this was secondary data, there was no way of 
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determining whether or not benzodiazepines were used as intended and for the prescribed length 
of time. For the purpose of this study, it was assumed that all benzodiazepine prescriptions were 
used fully; therefore, the terms benzodiazepine prescribing, and benzodiazepine usage are used 
interchangeably throughout.   
3.2.2 Definition of Rural versus Urban  
Benzodiazepine usage was examined over a ten-year period, and differences between 
urban and rural usage were described. Statistics Canada’s definition of rural versus urban was 
used: those populations with less than 1,000 individuals being classified as rural (Statistics 
Canada, 2001). The 2011 Statistics Canada Census was used to determine community 
populations by NLCHI. During the fiscal years 2009, 2012 and 2013, the next available Medical 
Care Plan (MCP) code was used to obtain the postal code. This was completed by NLCHI prior 
to the team receiving the dataset.  
3.3 Methods 
3.3.1 Study Sample and Inclusion / Exclusion Criteria 
Research on benzodiazepines predominantly focuses on a senior population; however, 
usage of these drugs is not limited to this age group. Prescribing has been observed across all 
adult age groups. For this study, individual-level patient data from the NLPDP was used. All 
adults aged 18 and older that were prescribed a benzodiazepine in the NLPDP were included in 
the analysis.  
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3.3.2 Data Sources 
A ten-year period from April 2007 to March 2017 was used for analysis of 
benzodiazepine prescribing patterns year-over-year. Dates for this timeframe were based upon 
the fiscal year, for example: April 2007 to March 2008 for each of the ten years. 
 As noted, data for this study came from the NLPDP database. This database is comprised 
of participants in the five plans under the program: The Foundation Plan, the 65 Plus Plan, The 
Access Plan, The Assurance Plan and The Select Needs Plan. To access the data, ethics approval 
was first obtained by the Health Research Ethics Board, followed by a data application to NLCHI 
in March 2018. The full dataset was acquired in September 2018.  
3.3.3 Measuring Equivalent Benzodiazepine Usage  
Benzodiazepines can be classified into short-acting or long-acting drugs. As a result, it 
can be difficult to compare benzodiazepines in different classes. One example of this is 
diazepam, a long-acting benzodiazepine, compared to lorazepam, a short-acting benzodiazepine.  
Standardizing the various benzodiazepines to an equivalent dose of diazepam, allows for 
easier comparison. Table 3.1 was used to convert benzodiazepine usage to an equivalent 
benzodiazepine dosage of 5 mg of diazepam. These equivalences are recommended by the 
National Pain Centre at McMaster based upon the Canadian Pharmacy Association (1995) and 










Table 3.1. Equivalent Benzodiazepine Usage (McMaster University) 
 
Benzodiazepine  Equivalent to 5 mg diazepam (mg) 
Alprazolam 0.5 
Bromazepam 3 – 6 







Nitrazepam 5 – 10 
Oxazepam 15 
Temazepam 10 – 15 
Triazolam 0.25 
1Brandt, J., Alessi-Severini, S., Singer, A., & Leong, C. (2019). Novel Measures of Benzodiazepine and Z-Drug 
Utilisation Trends in a Canadian Provincial Adult Population (2001-2016). J Popul Ther Clin Pharmacol, 26(1), e22- 
e38. doi:10.22374/1710-6222.26.1.3 
2Manthey, L., Van Veen, T., Giltay, E. J., Stoop, J. E., Neven, A. K., Penninx, B. W. J. H., & Zitman, F. G. (2011).  
Correlates of (inappropriate) benzodiazepine use: the Netherlands Study of Depression and Anxiety (NESDA).  
71(2), 263-272. doi:10.1111/j.1365-2125.2010.03818.x 
3.3.4 Inappropriate Prescription   
For this study, a prescription was defined what was issued to an individual, regardless of 
duration or quantity of pills. Since the data is based upon prescription claims, a prescription was 
for each claim. Guidelines have recommended that benzodiazepine prescriptions be limited to a 
duration of two to four weeks. As such, an inappropriate prescription was analyzed using three 
different definitions to allow for comparison among them: 30 days, 45 days and 60 days.  
If a prescription was dispensed within 30 days of the previous prescription being issued, it 
was classified as an inappropriate prescription. This method was repeated for 45 days and 60 




3.4 Outcome Measures 
3.4.1 Benzodiazepine Usage 
Benzodiazepine usage was measured using a variety of indicators: duration of 
prescription, quantity prescribed and percentage of inappropriate benzodiazepine prescriptions. 
For this study, it was assumed that all individuals who were prescribed a benzodiazepine used the 
medication for the duration of the prescription.  
3.4.2 Prescription Duration 
Duration of prescription was measured as the duration of the medication in days. 
3.4.3 Quantity Prescribed  
Quantity prescribed was measured using two metrics. Quantity dispensed was the total 
number of pills that a patient was prescribed. Quantity per day was measured as the quantity 
dispensed divided by the prescription duration. For example, if the quantity prescribed was 60 
days, and prescription duration was 30 days, then the quantity per day was calculated as 2 per 
day.  
3.4.4 Aggregate Quantity Prescribed 
Using the quantity prescribed and the diazepam equivalent, an aggregate quantity 
prescribed was calculated by multiplying the 5 mg equivalent of diazepam by the quantity 
prescribed. Using this measure allows for comparisons between different durations and type of 
benzodiazepines, for example: comparing a 14-day prescription of lorazepam and a 60-day 
prescription of diazepam.  
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3.4.5 Inappropriate Prescription 
Various guidelines have reported that benzodiazepines should be restricted to 30 days or 
less (Copperstock & Hill, 1982; APA, 1990; WHO, 1996; Katzman et al., 2014). For this study, 
an inappropriate prescription was defined as inappropriate if a new prescription was issued within 
30 days of the previous prescription ending. Three different durations (30, 45 and 60 days) were 
used to analyze the inappropriate prescription rate based upon the three definitions of an 
inappropriate prescription. Percentage of inappropriate prescriptions was calculated as the 
number of inappropriate prescriptions divided by the total number of prescriptions (ranging from 
0 to 1.0). A linear regression was used to examine the association between variables and the 
percentage of inappropriate prescriptions for 30, 45 and 60 days between prescriptions.   
3.4.6 Dispensed Days’ Supply  
 Dispensed days’ supply was defined as the duration for which a prescription was issued.  
3.4.7 Drug Generic Name 
Drug generic names were reported as medication corresponding to the appropriate 
benzodiazepine.  
3.5 Data Analysis 
3.5.1 Sample Size 
 All participants who were part of the NLPDP that were prescribed a benzodiazepine were 
included in this study. There were 63,517 unique individuals who were prescribed a 
benzodiazepine from 2007 to 2016 in Newfoundland.  
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3.5.2 Statistical Analysis 
                        3.5.2.1 Descriptive Statistics 
 
Descriptive statistics were used to summarize the population and demographic 
characteristics. Frequencies and percentages were used to assess the categorical variables 
for quantity dispensed, dispensed days’ supply, drug generic name, and prescriber 
specialty. Age was calculated based on the first prescription that an individual received. A 
chi-squared test was used to examine the difference between urban and rural areas. For 
the variables with expected cell counts less than 5, Fisher exact tests were used.  
Means and standard deviation were used to described continuous variables 
including quantity dispensed, dispensed days average pills per day, drug strength, 
diazepam equivalent and aggregate quantity prescribed. Differences between rural and 
urban areas were examined by a t-test. Statistical significance was determined at p < 0.05. 
All analyses were conducted using SAS software version 9.4 (SAS Institute, Cary NC).  
  3.5.2.2 Linear Regression  
 
Linear regression was used in the multivariate analyses to identify significant risk 
factors for number of inappropriate prescriptions, as well as the percentage of 
inappropriate prescriptions. Effects of residence location (urban / rural), age, sex and 
prescriber specialty were examined, and the interaction term of age and urban / rural 
status.  
The independent variable used for the regression analyses was the number of total 
inappropriate prescriptions, and the percentage of inappropriate prescriptions. Rural / 
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urban status was the dependent variable with age group, prescriber specialty and sex were 
the covariates used in the analyses. Lower order terms were included when assessing the 
interaction term of age and urban/rural status.  In Newfoundland, there are age differences 
in urban areas compared to rural areas. For example, in St. John’s, the median age is 39.4 
years while in St. Anthony the median age is 49 years (Statistics Canada, 2017). 
After conducting the linear regression, model diagnostics were examined visually 
for any outliers using a plot of Cook’s distance (Appendix 3). If there were outliers, they 
were examined individually and the effect of removing them on the estimates. Similarly, a 
plot of studentized residuals was examined to assess the appropriateness of using a linear 
regression for the analyses (Appendix 3). All analyses were conducted using SAS 
software, the genmod procedure, version 9.4 (SAS Institute, Cary NC). 
3.6 Ethics and Confidentiality 
This study was approved by the Health Research Ethics Board in Newfoundland and 
Labrador. Prior to accessing the secondary data, a separate approval was obtained from NLCHI 
regarding confidentiality. Each study participant was given an identification number by NLCHI. 
Any information that included identifiable information was held by NLCHI and not released to 


































Chapter 4: Results 
 This chapter presents the study findings in four sections. Demographics and baseline 
characteristics of benzodiazepine prescribing are described in the first section. The second section 
provides an overview of various metrics for benzodiazepine prescribing / usage, including 
quantity dispensed and prescription duration. Comparisons between mean values for 
benzodiazepine usage variables including quantity dispensed, equivalent milligrams of diazepam 
equivalence and drug strength are compared in the third section. Lastly, factors associated with 
inappropriate benzodiazepine prescribing are explored using multivariate linear regression.   
4.1 Sample Characteristics 
 
All individuals, over the age of 18, who were prescribed a benzodiazepine between 2007 
and 2016 were included in this study; a total of 63,517 individuals. Table 4.1 shows the various 
prescription claim status’. Over 90% of individuals prescribed a benzodiazepine were categorized 
as “SETTLED-PAID”, which refers to a prescription for which reimbursement was processed. 
For this category, it was assumed that all the medications which were prescribed were used by the 
patient.   
 
Table 4.1 – Prescription Claim Status 
 
Prescription Claim Status Frequency (%) 
IN ERROR – RETURN TO PROVIDER 118,793 (5.61) 
SETTLED – CANCELLED 5 (0.00) 
SETTLED – PAID 1,915,086 (90.51) 
SETTLED – REVERSED 80,429 (3.80) 
TO PAY – TO PAY 1 (0.00) 





Table 4.2 – Benzodiazepine Prescriptions among Study Sample 
 
Year1 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Total 





















































1Year refers to the fiscal year. 
2Total number of individuals if summed is 214,112. Number of unique ids / individuals is 63,517. 
3This is the total number of prescriptions, including all prescription claim status  
 
 
When analyzing benzodiazepine prescriptions all 2,115,856 prescriptions were used 
however when analyzing benzodiazepine usage, only the “Settled-Paid” prescriptions were used.  
Table 4.2 shows the total number of prescriptions and individuals in each year. Between 
2007 and 2016 the percentage of benzodiazepines that were prescribed to an individual in a rural 
area varied between 18.06% and 19.54%. In 2007 18,778 individuals received 180,182 












Table 4.3 – Patient Demographics  








































p < 0.01 
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p < 0.01 
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p < 0.01 
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p = 0.29 
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p = 0.50 




































p < 0.01 
 
 













p = 0.97 




































p < 0.01 
 
 













p = 0.55 




































p < 0.01 
 
 













p = 0.35 




































p < 0.01 
 
 













p = 0.74 
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N 5,504 18,875 24,379  
          1 t-tests used for comparing continuous variables (mean age). Chi-squared tests used for categorical variables    
         (age groups and sex) 
        2Age was calculated based on the first prescription that an individual received  
 
 Mean age varied across the ten-year period. Individuals in rural areas had a higher mean 
age than those in urban areas by approximately 3 years. The distribution of age groups varied 
between rural and urban areas, specifically a higher percentage of individuals were in the 65-84 
age group in rural areas. Percentage of females did not vary significantly between urban and rural 
















4.2 Benzodiazepine Prescribing / Usage 
 
Benzodiazepine prescribing was analyzed using quantity dispensed, dispensed days’ 
supply and diazepam equivalents. This section will focus on frequencies and percentages of these 
variables.  



























































































































































































































































































































































































































































































































1 Quantity of pills dispensed in number of pills: n (%) 
2 7-14: greater than 7 and less than 14; 14-30: greater than or equal to 14 and less than 30; 30-45: greater than 30 and    
  less than 45; 45-60: greater than or equal to 45 and less than 60 
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3 p-value is the comparison between rural and urban 
 
 
Table 4.4 shows the distribution of quantities dispensed. The most commonly prescribed 
benzodiazepine quantities (measured in pills) were 30, 60 and more than 60 pills. Approximately 
30% of prescriptions per year were for a quantity of 30 pills and 20% were for a quantity of 60 




















Table 4.5 – Number of Prescriptions Stratified by Dispensed Days’ Supply 
 
Year 































































































































































































































































































































































































































































































1 Dispensed days supply measured in days: n (%)  
27-14: greater than 7 and less than 14; 14-30: greater than or equal to 14 and less than 30; 30-45: greater than 30 and 
less than 45; 45-60: greater than or equal to 45 and less than 60  
3 p-value is the comparison between rural and urban 
 
Table 4.5 shows the number of prescriptions in each category, stratified by rural / urban 
area across ten years. The two most frequently prescribed durations were 14-30 days and 30 days, 







 Table 4.6 – Number of Prescriptions Stratified by Drug Generic Name (All Years) 
 









































































































p < 0.01 































































































Null  1  
 Total 2,115,856  
1Measured as number of prescriptions (%) 





Lorazepam was the most commonly prescribed benzodiazepine, comprising 35% of total 
prescriptions. Clonazepam and temazepam were the second and third-most prescribed 
benzodiazepine with 22% and 14%, respectively. Table 4.6 shows the breakdown of prescriptions 
by drug generic name, with a significant higher number of prescriptions (greater than 50%) being 
issued to individuals in urban areas compared to rural areas.  
Across the ten-year timeframe, clonazepam increased from year 1 to the last year 
examined. Similarly, increases were observed in lorazepam across the timeframe. Table 4.7 


















Table 4.7 – Number of Prescriptions Stratified by Drug Generic Name 
 
 
Drug Generic Name – Year by Year1 
















































































































































































































































































































































Total 180,182 188,028 189,979 211,271 222,993 224,384 225,731 225,768 223,406 224,114 
1Measured as number of persons (%). Percentages are shown based on each year (i.e., 5.2% of benzodiazepine 




































































































































































































































                     1Other: any prescriber specialty except for general practitioner (GP)
                
                 2Measured as number of prescriptions: n (%)
 
                     3Comparison between rural and urban by prescriber specialty using chi-squared test 
              
 
 
Across all years, more than 95% of prescriptions were written by general practitioners 
(GPs). In year 1, 99.36% of prescriptions were from GPs compared to 0.64% from other 
specialities. Interestingly, when stratifying by prescriber specialty differences were observed 
between rural and urban areas. Furthermore, between April 2012 and March 2013 19.23% of 
prescriptions by a GP where to an individual living in a rural area compared to 40.19% of those 
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by any other prescriber specialty.   Table 4.8 shows the distribution of prescriptions between rural 
and urban areas.  
4.3 Average Benzodiazepine Usage 
 
Table 4.9 – Sex, Prescriber and Location Frequencies  
 
Variable 
Sample Size  
n (%) 
Male 772,764 (36.5) 
Female 1,343,092 (63.5) 
GP 2,082,301 (98.4) 
Other1 33,555 (1.6) 
Urban 1,713,309 (81.0) 
Rural 402,547 (19.0) 
Total 2,115,856 (100.0) 
          1Other: any prescriber specialty except for general  
        practitioner (GP) 
 
The total frequencies and percentages of prescriptions by sex, prescriber specialty and 
urban / rural classification are shown in Table 4.9. Benzodiazepines were more frequently 
prescribed to females, by GPs and to those residing in urban areas (defined as greater than 1,000 






Table 4.10- Average Quantity Dispensed1 
 
Variable  Mean (Std Dev)2 
Sample Size 
(n) 
Min / Max2 p-value3 
Male 
Rural 51.90 (34.6) 144,719 0.20 / 280 
p < 0.01 
Urban 51.0 (37.8) 626,703 0.5 / 280  
Female 
Rural 51.8 (33.1) 257,444 0.5 /280 p < 0.01 
Urban 50.9 (35.8)  1,084,582 0.2 / 284  
GP 
Rural 51.9 (33.7)  392,813 0.2 / 280 p < 0.01 
Urban 51.1 (36.6) 1,687,093 0.2 / 284  
Other3 
Rural 47.2 (29.6) 9,350 0.5 / 280 p < 0.01 
Urban 43.6 (34.4) 24,192 0.2 / 270  
Urban  51.0 (36.6)  1,711,285 0.2 / 284 p < 0.01 
Rural  51.8 (33.6)  402,163 0.2 / 280 
 
Age: 18 - 24 
Rural 41.4 (32.8)  5,741 0.5 / 270 p = 0.89 
Urban 41.3 (34.3) 35,389 1 / 270  
Age: 25 - 44 
Rural 51.7 (39.3) 46,757 0.2 / 280 p < 0.01 
Urban 46.2 (37.2) 324,685 0.2 / 280   
Age: 45 - 64 
Rural 53.9 (35.9)  136,499 0.5 / 280  p < 0.01 
Urban 52.8 (39.1) 659,783  0.5 / 280   
Age: 65 - 84 
Rural 51.9 (31.1) 187,561 1 / 270  p < 0.01 
Urban 53.9 (34.5) 573,266 0.5 / 280   
Age: 85 + 
Rural 42.4 (24.9) 25,605 1 / 270  P = 0.32 
Urban 42.2 (25.6) 118,162 0.5 / 284  
Total  51.12 (36.02) 2,113,448 0.2 / 284  
        1 Quantity dispensed measured as number of pills  
      2Outliers removed using 3*SD: (3*77.64). Using 2,115,856 prescriptions: mean = 51.57, std dev = 77.64 
        3 p-value is the comparison between rural and urban 




Overall, 51 pills were dispensed per prescription (Table 4.10). This was approximately 
equal when comparing sex and place of residence. When comparing individuals in the 25-44 age 
group, those living in a rural area were prescribed an average of 5 more pills than those living in 
an urban area. Quantities dispensed were higher in rural areas, with minimal differences between 





















Table 4.11- Average Dispensed Days’ Supply1 
 
Variable  Mean (Std Dev) Sample Size (n) Min / Max2 p-value3 
Male 
Rural 26.4 (7.91) 142,473 0 / 57 
 
p < 0.01 
Urban 23.6 (9.94) 620,994  0 / 58 
 
Female 
Rural 27.1 (6.86) 253,296  0 / 59 p < 0.01 
Urban 25.0 (8.94)  1,070,846 0 / 58  
GP 
Rural 26.9 (7.26) 386,499 0 / 59 p < 0.01 
Urban 24.5 (9.31) 1,667,762 0 / 58  
Other4 
Rural 26.8 (7.40)  9,270  0 / 56 p < 0.01 
Urban 21.6 (10.6)  24,078 0 / 56  
Urban  24.5 (9.34)  1,691,840 0 / 58 p < 0.01 
Rural  26.9 (7.26) 395,769 0 / 59  
Age: 18 - 24 
Rural 20.5 (10.3)  5,720 1 / 54 p < 0.01 
Urban 19.8 (10.7)  35,279  1 / 56  
Age: 25 - 44 
Rural 23.5 (9.68)  46,484  0 / 57 p < 0.01 
Urban 20.5 (11.1)  322,939 0 / 56  
Age: 45 - 64 
Rural 26.0 (8.32) 135,142 0 / 56 p < 0.01 
Urban 23.3 (10.0) 655,332 0 / 57  
Age: 65 - 84 
Rural 28.4 (5.03) 183,272 0 / 59 p < 0.01 
Urban 27.8 (5.91) 561,651 0 / 58  
Age: 85 + 
Rural 28.0 (4.92) 25,151 1 / 56 p < 0.01 
Urban 27.2 (6.19) 116,639 0 / 56  
Total  24.91 (9.03) 2,087,609 0 / 59  
            1Average dispensed days supply measured as number of days 
            2Outliers removed using 3*SD: (3*11.29). Using 2,115,856 prescriptions: mean = 25.68, std dev = 11.29 
            3p-value is the comparison between rural and urban 





Overall, the average duration of a benzodiazepine prescription was 25 days. Those in rural 
areas had a higher mean duration by approximately two days (Table 4.11). Among individuals 
25-44, those living in a rural area had a significantly higher mean dispensed days supply of 3 
days compared to those living in an urban area. Comparing within each of the 5 age groups, those 




















Table 4.12 – Average Number of Pills per Person per Day1 
Variable  
Mean 







Rural 1.95 (1.11)  144,297 0.066 / 10  p < 0.01 
Urban 2.21 (1.31)  626,027 0.033 / 10   
Female 
Rural 1.90 (1.09) 257,485 0.066 / 10 p < 0.01 
Urban 2.07 (1.25) 1,084,341 0.033 / 10  
GP 
Rural 1.92 (1.10) 392,434  0.066 / 10  p < 0.01 
Urban 2.12 (1.27)  1,686,289 0.033 / 10  
Other4 
Rural 1.78 (0.98) 9,348 0.048 / 10 p < 0.01 
Urban 2.09 (1.23) 24,079 0.067 / 10  
Urban  2.12 (1.27) 1,710,368 0.033 / 10 p < 0.01 
Rural  1.92 (1.10) 401,782 0.048 / 10  
Age: 18 - 24 
Rural 1.99 (1.10) 5,742 0.067 / 10 p < 0.01 
Urban 2.11 (1.24) 35,397 0.067 / 10  
Age: 25 - 44 
Rural 2.21 (1.28) 46,745 0.067 / 10 p < 0.01 
Urban 2.33 (1.35) 323,778 0.036 / 10  
Age: 45 - 64 
Rural 2.07 (1.17) 136,145 0.048 / 10 p < 0.01 
Urban 2.30 (1.35) 659,803 0.033 / 10  
Age: 65 - 84 
Rural 1.79 (0.98) 187,550 0.066 / 10 p < 0.01 
Urban 1.92 (1.13) 573,354 0.033 / 10  
Age: 85 + 
Rural 1.50 (0.84) 25,600 0.06 / 10 p < 0.01 
Urban 1.57 (0.93) 118,036 0.067 / 10  
Total 
 
2.08 (1.24) 2,112,150 0.033 / 10  
            1Average number of pills per person per day: n  
            2Outliers removed using 3*SD: (3*2.66). Using 2,115,840 prescriptions: mean = 2.11, std dev = 2.66 
            3p-value is the comparison between rural and urban 
            4Other: any prescriber specialty except for general practitioner (GP) 




Table 4.12 indicates the average number of pills per day was 2.08. Individuals living in an 
urban area were prescribed more pills per day on average, than those living in a rural area. 
Among individuals in the 45-64 age group, individuals living in an urban area were prescribed 
more pills per day than those living in a rural area. Comparing values within age groups, those 





















Table 4.13 - Drug Strength1 
Variable  Mean (Std Dev) Sample Size (n) Min / Max2 p-value3 
Male 
Rural 6.72 (9.92) 144,889 0.125 / 30 p < 0.01 
Urban 7.24 (10.30) 627,865 0.125 / 30  
Female 
Rural 5.39 (8.84) 257,651 0.125 / 30 p < 0.01 
Urban 6.28 (9.73) 1,085,431 0.125 / 30  
GP 
Rural 5.87 (9.27)  393,190  0.125 / 30 p < 0.01 
Urban 6.66 (9.96)  1,689,098 0.125 / 30  
Other4 
Rural 5.96 (9.03) 9,350 0.125 / 30 p < 0.01 
Urban 4.69 (8.10) 24,198 0.125 / 30  
Urban  6.63 (9.94) 1,713,296 0.125 / 30 p < 0.01 
Rural  5.87 (9.27) 402,540 0.125 / 30  
Age: 18 - 24 
Rural 4.34 (7.83) 5,744 0.125 / 30 p < 0.01 
Urban 3.75 (7.26) 35,488 0.125 / 30  
Age: 25 - 44 
Rural 4.22 (7.62) 46,798 0.125 / 30 p < 0.01 
Urban 5.40 (9.18) 324,967 0.125 / 30  
Age: 45 - 64 
Rural 6.06 (9.52) 136,756 0.125 / 30 p < 0.01 
Urban 7.14 (10.30) 660,774 0.125 / 30  
Age: 65 - 84 
Rural 6.05 (9.39) 187,634 0.125 / 30 p < 0.01 
Urban 6.83 (9.98) 573,894 0.125 / 30  
Age: 85 + 
Rural 6.90 (9.58) 25,608 0.125 / 30 p < 0.01 
Urban 7.14 (9.78) 118,173 0.125 / 30  
Total  6.50 (9.82) 2,115,836 0.125 / 30  
            1Drug strength measured in milligrams (mg)  
            2Outliers removed using 3*SD: (3*9.82). Using 2,115,836 prescriptions: mean = 6.49, std dev = 9.82 
            3p-value is the comparison between rural and urban 
            4Other: any prescriber specialty except for general practitioner (GP) 
 
 
Mean drug strength for all prescriptions was 6.50 milligrams (Table 4.13). Among males, 
those living in an urban area were prescribed a higher drug strength than those in a rural area. 
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Overall, those living in an urban area had a higher average prescription drug strength than those 
in rural areas. It is important to note that this does not account for the difference in potency of the 

































Rural 2.82 (3.54) 144,889 0.27 / 12 p < 0.01 
Urban 3.31 (3.93) 627,865 0.27 / 12  
Female 
Rural 2.31 (3.05) 257,651 0.29 / 12 p < 0.01 
Urban 2.81 (3.56) 1,085,430 0.27 / 12  
GP 
Rural 2.50 (3.25) 393,190 0.27 / 12 p < 0.01 
Urban 3.00 (3.71) 1,689,097 0.27 / 12  
Other4 
Rural 2.25 (2.99) 9,350 0.29 / 12 p < 0.01 
Urban 2.41 (3.16) 24,198 0.27 / 12  
Urban  2.99 (3.71) 1,713,295 0.27 / 12 p < 0.01 
Rural  2.49 (3.24) 402,540 0.27 / 12  
Age: 18 - 24 
Rural 1.95 (2.65) 5,744 0.29 / 12 p = 0.98 
Urban 1.95 (2.68) 35,488 0.27 / 12  
Age: 25 - 44 
Rural 2.12 (2.80) 46,798 0.29 / 12 p < 0.01 
Urban 2.81 (3.59) 324,967 0.29 / 12  
Age: 45 - 64 
Rural 2.71 (3.45) 136,756 0.29 / 12 p < 0.01 
Urban 3.37 (3.98) 660,774 0.27 / 12  
Age: 65 - 84 
Rural 2.44 (3.19) 187,634 0.27 / 12 p < 0.01 
Urban 2.80 (3.52) 573,893 0.27 / 12  
Age: 85 + 
Rural 2.53 (3.28) 25,608 0.29 / 12 p < 0.01 
Urban 2.64 (3.35) 118,173 0.27 / 12  
Total  2.90 (3.63) 2,115,835 0.27 / 12  
            1Number of 5 mg diazepam equivalents. For example: 0.5 mg of alprazolam is equivalent to 5 mg of diazepam.      
         Therefore, a drug strength of 2 mg of alprazolam would be equivalent to 4-5mg diazepam equivalents.  
            2Outliers removed using 3*SD: (3*3.63). Using 2,115,856 prescriptions: mean = 2.90, std dev = 3.63 
            3p-value is the comparison between rural and urban 





The average number of diazepam equivalents was 2.90 (Table 4.14). Comparing within 
sex, males that lived in an urban area had a higher average number of diazepam equivalents than 
males living in a rural area. Similarly, results were observed in females, with those living in 
urban areas having a higher average number of diazepam equivalents than females living in a 
rural area.  Among individuals in the 45-64 age group, the average number of diazepam 































Rural 110.0 (129.0)  142,538 0.27 / 720 p < 0.01 
Urban 125.0 (150.0) 612,212 0.33 / 735  
Female 
Rural 96.4 (113.0) 256,158 0.25 / 730 p < 0.01 
Urban 110.0 (133.0) 1,073,321 0.13 / 725  
GP 
Rural 102.0 (199.0) 389,405 0.27 / 720 p < 0.01 
Urban 116.0 (140.0) 1,661,581 0.13 / 735  
Other4 
Rural 84.3 (99.0) 9,291  0.25 / 720 p < 0.01 
Urban 79.0 (97.1) 23,952 0.20 / 720  
Urban  115.0 (140.0) 1,685,533 0.13 / 735 p < 0.01 
Rural  101.0 (119.0) 398,696 0.25 / 720  
Age: 18 - 24 
Rural 69.6 (94.0) 5,719 0.25 / 720 p = 0.96 
Urban 69.6 (101.0) 35,242 0.5 / 720  
Age: 25 - 44 
Rural 88.3 (109.0) 46,372 0.27 / 720 p < 0.01 
Urban 101.0 (136.0) 320,224 0.13 / 720  
Age: 45 - 64 
Rural 108.0 (128.0) 134,663 0.33 / 720 p < 0.01 
Urban 125.0 (150.0) 643,823 0.17 / 735  
Age: 65 - 84 
Rural 102.0 (116.0) 186,396 0.67 / 720 p < 0.01 
Urban 119.0 (135.0) 568,323 0.5 / 720  
Age: 85 + 
Rural 90.6 (107.0) 25,546 0.67 / 720 p < 0.01 
Urban 93.5 (115.0) 117,921 0.5 / 720  
Total  112.49 (136.20) 2,084,229 0.133 / 735  
            1Aggregate quantity measured as quantity of pills dispensed * number of 5 mg diazepam equivalents. For      
         example: 10 pills of 2.0 mg alprazolam (equivalent to 4-5mg diazepam equivalents) would be equal to an  
         aggregate quantity of 40 pills of 5 mg diazepam equivalents.   
            2Outliers removed using 3*SD: (3*203.22). Using 2,115,856 prescriptions: mean = 126.42, std dev = 203.22 
            3p-value is the comparison between rural and urban 




The average aggregate quantity prescribed was 112.49 (136.2) pills of 5mg diazepam 
equivalent. Those in urban areas had a significantly higher quantity of pills 5mg diazepam 
equivalent compared to those in rural areas (115 vs 101) (Table 4.15). Similarly, among males 
there was a higher average aggregate quantity in those living in an urban area compared to those 
living in a rural area. Among the 25-44 age group, those living in an urban area had an average of 
101 pills of 5mg diazepam equivalent compared to 88.3 in those living in a rural area.  
4.4 Inappropriate Prescription Regression Analyses  
4.4.1 Prescriptions within 30 days 
The total number of prescriptions was 2,115,856 and the total number of inappropriate 
prescriptions was 1,515,931. Therefore, the ratio of inappropriate prescriptions was 71.65% when 
using prescriptions less than 30 days apart. Tables 4.16 and 4.17 display the results of the 
regression analysis predicting both the total number and percentage of inappropriate prescriptions 











    Table 4.16 – Linear Regression Results for Total Number of Inappropriate Prescriptions 
within 30 days 
 
Variable1 Estimate Standard 
Error 
95% CI  P value 
Intercept 3.92 0.122 3.69 to 4.16  
Sex     p < 0.052 
Female 
(ref) 
-    
Male -0.168 0.0705 -3.06 to -0.0294  
Prescriber 
Specialty            
   p = 0.922 
GP 
(ref) 
-    
Other -0.0188 0.181 -0.374 to 0.336  
Age Group *  
Urban / Rural 
   p < 0.012 
Urban     
Age Group     
18 – 24 -2.26 0.203 -2.65 to -1.86 p < 0.013 
25 – 44 -0.26 0.147 -0.545 to 0.033 p = 0.083 
45 - 64 1.06 0.143 0.781 to 1.340 p < 0.013 
65 - 84 -0.205 0.136 -0.472 to 0.0628 p = 0.133 
85+ 
(ref) 
-    
Rural     
Age Group     
18 - 24 -2.22 -2.22 -3.08 to -1.36 p < 0.013 
25 - 44 -1.13 -1.13 -1.75 to -0.504 p < 0.013 
45 - 64 -0.375 -0.375 -0.949 to 0.199 p = 0.203 
65 - 84 -0.347 -0.347 -0.896 to 0.202 p = 0.223 
85+ 
(ref) 
-    
          
 1Dependent variable: number of inappropriate prescriptions; independent variable: urban/rural status;   
          covariates: sex, prescriber specialty, age group; interaction term: age group*urban rural status 
           2Analysis of Variance (ANOVA)/ Type 3 Sum of Squares test 
















Table 4.17 – Linear Regression Results for Percentage of Inappropriate Prescriptions within 30 
days  
 
Variable1 Estimate Standard 
Error 
95% CI  P value 
Intercept 0.415 0.0048 0.406 to 0.424  
Sex     p < 0.012 
Female 
(ref) 
-    
Male -0.0091 0.00279 -0.0146 to -0.0036  
Prescriber 
Specialty            
   p = 0.122 
GP 
(ref) 
-    




Age Group *  
Urban / Rural 
   p < 0.012 
Urban     
Age Group     
18 - 24 -0.198 0.0080 -0.214 to -0.183 p < 0.013 
25 - 44 -0.112 0.0058 -0.124 to -0.101 p < 0.013 
45 - 64 -0.0401 0.0057 -0.0512 to -0.0291 p < 0.013 
65 - 84 -0.0324 0.0054 -0.0430 to -0.0218 p < 0.013 
85+ 
(ref) 
-    
Rural     
Age Group     
18 - 24 -0.228 0.0174 -0.2617 to -0.1934 p < 0.013 
25 - 44 -0.147 0.0126 -0.172 to -0.123 p < 0.013 
45 - 64 -0.0842 0.0116 -0.107 to -0.0615 p < 0.013 
65 - 84 -0.045 0.0111 -0.0668 to -0.0233 p < 0.013 
85+ 
(ref) 
-    
            1Dependent variable: percentage of inappropriate prescriptions; independent variable: urban/rural status;   
         covariates: sex, prescriber specialty, age group; interaction term: age group*urban rural status 
           2Analysis of Variance (ANOVA)/ Type 3 Sum of Squares test 
         3Result of comparison of marginal effects   
 
Table 4.16 shows results from the regression analysis for total inappropriate prescriptions 
within 30 days. After assessing the outliers and the impact on the estimates, two individuals were 
removed from the regression analysis for number of inappropriate prescriptions (no individuals 
were removed for the percentage of inappropriate prescriptions regression). Estimates prior to 
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removing the outliers and after removing the outliers are shown in Appendix 3. Similarly, 
diagnostic graphs for the regression analyses (plots of studentized residuals and Cook’s distance) 
are shown in Appendix 3.    
Males had a significantly lower average number of inappropriate prescriptions than 
females. A significant interaction term between urban/rural and age group was also observed in 
the multivariate regression model. Among people living in rural areas, compared to people aged 
85+, those in the 18-24 and 25-44 age group had a significantly lower average number of 
inappropriate prescriptions. Among people living in urban areas, in comparison with people aged 
85+, those in the 18-24 age group had a significantly higher average number of inappropriate 
prescriptions  while those in the 45-64 age group had a significantly higher average number of 
inappropriate prescriptions 
Results from the multivariate analysis using percentage of inappropriate prescriptions, 
within 30 days, is shown in table 4.17. Compared to females, males had a significantly lower 
average percentage of inappropriate prescriptions. A significant interaction term between 
urban/rural and age group was observed in the regression model. Among those living in an urban 
area, people in the 18-24, 25-44, 45-64 and 65-84 age groups had a significantly lower 
percentage of inappropriate prescriptions compared to people in the 85+ age group. Similarly, 
among people living in rural areas, those in the 18-24, 25-44, 45-64, 65-84 age groups had a 







4.4.2 Prescriptions within 45 days 
The ratio of inappropriate prescriptions was 73.41% when using prescriptions less than 45 
days apart. Tables 4.18 and 4.19 display the results of the regression analysis for: the total 
number and percentage of inappropriate prescriptions within 45 days. After assessing the outliers 
and the impact on the estimates, two individuals were removed from the regression analysis for 
number of inappropriate prescriptions (no individuals were removed for the percentage of 
inappropriate prescriptions regression). Estimates prior to removing the outliers and after 
removing the outliers are shown in Appendix 3. Similarly, diagnostic graphs for the regression 
analyses (plots of studentized residuals and Cook’s distance) are shown in Appendix 3. When 















Table 4.18 – Linear Regression Results for Total Number of Inappropriate Prescriptions within 
45 days 
 
Variable1 Estimate Standard 
Error 
95% CI  P value 
Intercept 4.03 0.124 3.79 to 4.26  
Sex     p < 0.052 
Female 
(ref) 
-    
Male -0.169 0.0716 -0.309 to -0.354  
Prescriber 
Specialty            
   p = 0.972 
GP 
(ref) 
-    
Other -0.0071 0.0716 -0.3678 to 0.354  
Age Group *  
Urban / Rural 
   p < 0.012 
Urban     
Age Group     
18 - 24 -2.32 0.206 -2.72 to -1.91 p < 0.013 
25 - 44 -0.270 0.150 -0.564 to 0.0235 p = 0.073 
45 - 64 1.10 0.145 0.814 to 1.382 p < 0.013 
65 - 84 -0.216 0.139 -0.487 to 0.056 p = 0.123 
85+ 
(ref) 
-    
Rural     
Age Group     
18 - 24 -2.27 0.447 -3.14 to -1.39 p < 0.013 
25 - 44 -1.16 0.324 -1.79 to -0.525 p < 0.013 
45 - 64 -0.362 0.298 -0.945 to 0.221 p < 0.013 
65 - 84 -0.351 0.285 -0.909 to -0.351 p = 0.223 
85+ 
(ref) 
-    
            1Dependent variable: number of inappropriate prescriptions; independent variable: urban/rural status;   
         covariates: sex, prescriber specialty, age group; interaction term: age group*urban rural status 
           2Analysis of Variance (ANOVA)/ Type 3 Sum of Squares test 
         3Result of comparison of marginal effects   














      Table 4.19 – Linear Regression of Percentage of Inappropriate Prescriptions within 45 days  
 
Variable1 Estimate Standard 
Error 
95% CI  P value 
Intercept 0.430 0.00490 0.420 to 0.440  
Sex     p < 0.012 
Female 
(ref) 
-    
Male -0.0091 0.0028 -0.0147 to -0.0036  
Prescriber 
Specialty            
   p = 0.132 
GP 
(ref) 
-    
Other -0.0109 0.0073 -0.0252 to 0.0034  
Age Group *  
Urban / Rural 
   p < 0.012 
Urban     
Age Group     
18 - 24 -0.206 0.0082 -0.222 to -0.190 p < 0.013 
25 - 44 -0.116 0.0059 -0.128 to -0.104 p < 0.013 
45 - 64 -0.0403 0.0057 -0.0516 to -0.0291 p < 0.013 
65 - 84 -0.0341 0.0055 -0.0448 to -0.0233 p < 0.013 
85+ 
(ref) 
-    
Rural     
Age Group     
18 - 24 -0.235 0.0177 -0.270 to -0.201 p < 0.013 
25 - 44 -0.153 0.0128 -0.178 to -0.128 p < 0.013 
45 - 64 -0.0867 0.0118 -0.110 to -0.0636 p < 0.013 
65 - 84 -0.0488 0.0113 -0.071 to -0.0267 p < 0.013 
85+ 
(ref) 
-    
            1Dependent variable: percentage of inappropriate prescriptions; independent variable: urban/rural status;   
         covariates: sex, prescriber specialty, age group; interaction term: age group*urban rural status 
           2Analysis of Variance (ANOVA)/ Type 3 Sum of Squares test 
         3Result of comparison of marginal effects   
 
Table 4.18 shows results from the regression analysis for total inappropriate prescriptions 
within 45 days. Males had a significantly lower average total inappropriate prescriptions than 
females. A significant interaction term between urban/rural and age group was also observed in 
the multivariate regression model.  Among people living in rural areas, in comparison with 
people aged 85+, people aged 18-24 and 25-44 had a significantly lower average number of 
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inappropriate prescriptions. Similarly, among people living in urban areas, people aged 18-24 had 
a significantly lower average number of inappropriate prescriptions compared to people in the 
85+ age group while those in the 45-64 age group had a significantly higher number of 
inappropriate prescriptions.  
Results from the multivariate analysis using percentage of inappropriate prescriptions, 
within 45 days, is shown in table 4.19. Compared to females, males had a significantly lower 
average percentage of inappropriate prescriptions. A significant interaction term between 
urban/rural and age group was observed in the regression model. Among those living in an urban 
area, people in the 18-24, 25-44, 45-64 and 65-84 age groups had a significantly lower average 
percentage of inappropriate prescriptions compared to people in 85+ age group. Similarly, among 
people living in rural areas, those in the 18-24, 25-44, 45-64 and 65-84 age groups had a 
significantly lower average percentage of inappropriate prescriptions compared to people in the 










4.4.3 Prescriptions within 60 days 
The ratio of inappropriate prescriptions was 74.88% when using prescriptions less than 60 
days apart. Tables 4.20 and 4.21 display the results of the regression analysis predicting both the 
total number and percentage of inappropriate prescriptions within 60 days.  
After assessing the outliers and the impact on the estimates, two individuals were 
removed from the regression analysis for number of inappropriate prescriptions (no individuals 
were removed for the percentage of inappropriate prescriptions regression). Estimates prior to 
removing the outliers and after removing the outliers are shown in Appendix 3. Similarly, 
diagnostic graphs for the regression analyses (plots of studentized residuals and Cook’s distance) 















Table 4.20 – Linear Regression Results for Total Number of Inappropriate Prescriptions within 
60 days 
 
Variable1 Estimate Standard 
Error 
95% CI  P value 
Intercept 4.14 0.126 3.89 to 4.38  
Sex     p < 0.052 
Female 
(ref) 
-    
Male -0.175 0.0727 -0.317 to -0.0323  
Prescriber 
Specialty            
   p = 0.992 
GP 
(ref) 
-    
Other -0.0035 0.187 -0.369 to 0.362  
Age Group *  
Urban / Rural 
   p < 0.012 
Urban     
Age Group     
18 - 24 -2.38 0.209 -2.79 to -1.97 p < 0.013 
25 - 44 -0.304 0.152 -0.602 to -0.0066 p < 0.053 
45 - 64 1.10 0.147 0.816 to 1.39 p < 0.013 
65 - 84 -0.237 0.141 -0.513 to 0.0384 p = 0.093 
85+ 
(ref) 
-    
Rural     
Age Group     
18 - 24 -2.33 0.453 -3.22 to -1.45 p < 0.013 
25 - 44 -1.20 0.328 -1.84 to -0.56 p < 0.013 
45 - 64 -0.392 0.302 -0.98 to 0.20 p = 0.193 
65 - 84 -0.382 0.289 -0.948 to 0.184 p = 0.193 
85+ 
(ref) 
-    
            1Dependent variable: number of inappropriate prescriptions; independent variable: urban/rural status;   
         covariates: sex, prescriber specialty, age group; interaction term: age group*urban rural status 
           2Analysis of Variance (ANOVA)/ Type 3 Sum of Squares test 














    Table 4.21 – Linear Regression of Percentage of Inappropriate Prescriptions within 60 days 
 
Variable Estimate Standard 
Error 
95% CI  P value 
Intercept 0.443 0.0050 0.434 to 0.453  
Sex     p < 0.012 
Female 
(ref) 
-    
Male -0.0093 0.0029 -0.0149 to -0.0037  
Prescriber 
Specialty            
   p = 0.112 
GP 
(ref) 







Age Group *  
Urban / Rural 
   p < 0.012 
Urban     
Age Group     
18 - 24 -0.211 0.0083 -0.227 to -0.195 p < 0.013 
25 - 44 -0.120 0.0060 -0.132 to -0.109 p < 0.013 
45 - 64 -0.0421 0.0058 -0.0535 to -0.0307 p < 0.013 
65 - 84 -0.0358 0.0056 -0.0467 to -0.0249 p < 0.013 
85+ 
(ref) 
-    
Rural     
Age Group     
18 - 24 -0.242 0.0179 -0.277 to -0.207 p < 0.013 
25 - 44 -0.157 0.0130 -0.183 to -0.132 p < 0.013 
45 - 64 -0.0901 0.0119 -0.114 to -0.067 p < 0.013 
65 - 84 -0.0519 0.0114 -0.074 to -0.0295 p < 0.013 
85+ 
(ref) 
-    
             1Dependent variable: percentage of inappropriate prescriptions; independent variable: urban/rural status;   
         covariates: sex, prescriber specialty, age group; interaction term: age group*urban rural status 
           2Analysis of Variance (ANOVA)/ Type 3 Sum of Squares test 
         3Result of comparison of marginal effects   
 
Table 4.20 shows results from the regression analysis for total inappropriate prescriptions 
within 60 days. Males had a significantly lower average number of inappropriate prescriptions 
than females. A significant interaction term between urban/rural and age group was also observed 
in the multivariate regression model. Among people living in rural areas, in comparison with 
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people aged 85+, people aged 18-24 and 25-44 had a significantly lower average number of 
inappropriate prescriptions. Among people living in urban areas, in comparison with people aged 
85+, people aged 18-24 and 25-44 had a significantly higher average number of inappropriate 
prescriptions. Similarly, among people living in an urban area those in the 45-64 has a 
significantly higher average number of inappropriate prescriptions than those in the 85+ age 
group.  
Results from the multivariate analysis using percentage of inappropriate prescriptions, 
within 60 days, is shown in table 4.21. Compared to females, males had a significantly lower 
average percentage of inappropriate prescriptions. A significant interaction term between 
urban/rural and age group was observed in the regression model. Among those living in an urban 
area, people in the 18-24, 25-44, 45-64 and 65-84 age groups had a significantly lower average 
percentage of inappropriate prescriptions compared to people in the 85+ age group. Similarly, 
among people living in rural areas, those in the 18-24, 25-44, 45-64, 65-84 age groups had a 
significantly lower average percentage of inappropriate prescriptions compared to people in the 










4.5 Benzodiazepine Prescribing from 2007 to 2017 
 
Benzodiazepine prescribing fluctuated slightly from year to year. Figure 4.1 shows the 
difference in dispensed days’ supply from the fiscal year 2007 (April 2007 to March 2008) to the 
fiscal year 2016 (April 2016 to March 2017). Days’ supply remained between 27 and 29 over the 
10-year time frame for rural areas, and between 24 and 26 for urban areas.  
 
Figure 4.1 – Mean Dispensed Days’ Supply from 2007 to 2017 
Quantity of pills dispensed remained consistent between 50.5 and 53 for urban areas. For 
rural areas, the quantity was highest between April 2007 – March 2008 and lowest in the 2009 
































Figure 4.2 – Mean Quantity Dispensed from 2007 to 2017 
Quantity of pills dispensed remained consistent between 50.5 and 53 for urban areas. For 
rural areas, the quantity was highest between April 2007 – March 2008 and lowest in the 2009 
fiscal year.  
 
Figure 4.3 – Mean Aggregate Quantity from 2007 to 2017 
Figure 4.4 shows the average number of inappropriate prescriptions by year, with it being 

























































March 2017. Figure 4.5 shows similar results when analyzing the percentage of inappropriate 
prescriptions.  
 
Figure 4.4 – Number of Inappropriate Prescriptions from 2007 to 2017 
 
 






































































Chapter 5: Discussion and Conclusion 
5.1 Main Findings  
 
 Benzodiazepines are a class of drugs, which were initially intended to aid in treatment of 
a variety of indications, specifically anxiety and depression. As research increased on 
benzodiazepine usage, the prevalence of long-term usage was highlight. Furthermore, the 
association between adverse effects and long-term benzodiazepine use has been well-
documented. It is important to examine the prevalence of inappropriate benzodiazepine usage at 
various time points, to identify the rate of inappropriate prescribing.  
 This thesis analyzed benzodiazepine usage in Newfoundland (a subregion of the province 
of Newfoundland and Labrador (NL)) over a ten-year period; specifically comparing 
prescriptions between urban and rural areas in Newfoundland. Prescribing / usage patterns were 
assessed and compared to recommended guidelines. Linear regression analysis showed that 
benzodiazepine prescribing was frequently inappropriate, with over 70% of prescriptions being 
prescribed within 30 days of each other for the same individual. Furthermore, inappropriate 
prescribing was prevalent throughout the 10 years, with sex and the interaction term between age 
group and urban / rural areas, being significantly associated with inappropriate prescribing.  
These are key findings and highlight the need for promotion of appropriate prescribing 
guidelines to both practitioners and patients through ongoing continuing education efforts such as 
seminars, continuing medical education (CME) sessions or other efforts to increase awareness of 
inappropriate benzodiazepine usage to prescribers. We analyzed different benzodiazepine usage 
metrics including quantity and strength of benzodiazepine prescribed. We also analyzed derived 
variables such as aggregate quantities of diazepam equivalent. Across all study metrics, 
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overprescribing was evident. While drug therapy decisions are ultimately made by clinicians, 
knowledge translation strategies to share these results may improve prescribers’ decision making 
to alter the current overprescribing patterns.   
 Different interventions have been used to address benzodiazepine overprescribing. For 
example, Tannenbaum et al. (2014) analyzed the effects of an educational intervention in 
reducing benzodiazepine prescribing. In that study, both the intervention and control groups had 
an average of 9.9 medications per day; however, the intervention’s group average use was 9.6 
years compared to 11.2 years in the control group. This demonstrates that an educational 
intervention may be effective in reducing overprescribing. 
Other methods have included seminars and guidelines; however, reassessing usage after 
these interventions have been implemented would be necessary to determine the long-term 
effectiveness in decreasing benzodiazepine overprescribing. Research is needed to determine the 
most effective intervention. 
5.2 Interpretation of findings compared to previous published work  
 Five studies in particular will be used for comparison to the findings presented in this 
thesis: Manthey et al., 2011; Mattos et al., 2016; Jacob et al., 2017; Mokhar et al., 2018; and Weir 
et al., 2018. These studies provide insights regarding benzodiazepine usage and allow 
comparison to the current study’s sample and measures. Other relevant literature is included to 
allow comparison with study results; however, there remains limited research utilizing samples of 
all age groups and further studies could also elaborate on inappropriate durations of 
benzodiazepine usage.  
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5.2.1 Patient / Study Characteristics 
Overall, the current literature appears to focus on a population of seniors, with a paucity 
of studies focusing on urban and rural areas and younger age groups. To our knowledge, this is 
the first study that assessed benzodiazepine usage in a sample of Newfoundland adults aged 18 
and older, using a longitudinal study design. In this study, we also assessed urban and rural 
prescribing and usage. 
In the previous studies mentioned, some excluded patients under the age of 50 (Mattos et 
al., 2016; Jacob et al., 2017; Mokhar et al., 2018), while other study populations encompassed all 
adult ages (Manthey et al., 2011; Weir et al., 2018). The main objective of our study was to 
examine benzodiazepine usage in urban and rural areas of Newfoundland, among adults of all 
ages. Our sample described earlier in the thesis, included adults aged 18 years or older. Weir et 
al. (2018) included individuals 10 years of age, while Manthey et al. (2011) included ages 18 – 
65. For our study, the mean age was 57.19 (standard deviation was 19.66) ranging from 18 to 
105. Age groups that Weir et al. (2018) and Manthey et al. (2011) used were more similar to our 
study than those in the other three studies (Mattos et al., 2016; Jacob et al., 2017; Mokhar et al., 
2018).  
For our study, 80.97% of individuals were in living in urban areas compared to 19.03% in 
a rural area when they were first prescribed a benzodiazepine. Mattos et al. (2016) reported 
71.6% of participants to be urban-dwelling adults. Weymann et al. (2017) reported 94% of 
benzodiazepine users being in an urban area. Other researchers discussed in section 5.2 did not 
analyze urban versus rural areas.   
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Among the studies examined, the percent of females was 88.7 in Mattos et al. (2016), 
65.2% in Jacob et al. (2017), 62.79% in Weir et al. (2018), 66.1% in Manthey et al. (2011) and 
68.5% in Mokhar et al (2018). Our study had 63.12% females, which was similar to prior 
research.  
Over 63,500 individuals were included in our study, which allowed us to identify 
prescriptions in rural areas and stratify by drug generic names which may not be observable in 
studies with a smaller sample size. It is also possible that due to our large sample size, and 
consequently the power of our study, small differences were observed that may not be clinically 
relevant. Sample size varied amongst the studies explored in this section: 426 in Mattos et al. 
(2016), 32,182 in Jacob et al. (2017), 372,870 in Weir et al. (2018), 2,852 in Manthey et al. 
(2011) and 340 in Mokhar et al. (2018). Furthermore, among the 63,517 individuals in our study, 
2,115,856 prescriptions were prescribed throughout the ten-year period. Weir et al. (2018) 
examined 2,463,585 BZRA dispensations in 372,870 individuals; while similar in number to our 
sample, the study duration was only one year.  
One of the primary strengths of our study is that it is a ten-year longitudinal study, 
allowing for us to examine temporal trends prior to and after guidelines had been updated. Jacob 
et al. (2017) examined a four-year period, whereas Manthey et al. (2011) conducted an 8-year 
longitudinal analysis. Other researchers conducted studies for a period of one year (Mattos et al., 
2016; Weir et al., 2018; Mokhar et al., 2018). 
5.2.2 Benzodiazepine Prescribing Metrics 
 Various benzodiazepine metrics were analyzed: drug generic name, quantity dispensed, 
dispensed days’ supply, drug strength, diazepam equivalent and aggregate quantity.  
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For our study, the three most prescribed drugs were clonazepam (22.88%), lorazepam 
(35.42%) and temazepam (14.33%). Two of the previous studies reported the distribution of drug 
generic names. The top three benzodiazepines in one study were: tetrazepam, lorazepam and 
diazepam: 25.8%, 21.3% and 12.7%, respectively (Jacob et al., 2017). Mokar et al (2018) 
reported the top three as zopiclone (38.1%), oxazepam (18.1%) and lorazepam (13.8%). 
Lorazepam was the most prescribed benzodiazepine in our study, with it being the second most 
prescribed and third most prescribed in other studies (Jacob et al., 2017; Mokar et al., 2018).  
We also examined the mean quantity dispensed and dispensed days’ supply with results 
being 51.12 pills and 24.91 days. One of the previous studies had a mean dispensed days’ supply 
of 27 days (Weir et al., 2018) which was similar to the results from our study. Four of the other 
studies discussed did not examine dispensed days’ supply or the mean quantity dispensed and so 
could not be compared.  
Using the drug strength, a mean of 2.90 5mg diazepam equivalents was calculated in our 
study. Diazepam equivalent average was found to be 1.74 in our study, which was comparable to 
a defined daily dose of 1.0 in Weir et al. (2018) and 0.73 in Mokar et al. (2018).  
5.2.3 Benzodiazepine Use Stratified 
 A component of this study was to compare different benzodiazepine metrics described in 
sections 4.2 and 4.3 and to stratify them by sex, prescriber specialty, urban / rural status and age.  
 Differences were observed for quantity dispensed when comparing rural and urban areas 
stratifying by sex, prescriber specialty and urban/rural areas. Among individuals in the 25-44 age 
group, individuals living in a rural area were prescribed an average of 5 more pills than those 
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living in an urban area. Similarly, among individuals aged 45-64, those living in a rural area were 
prescribed an average of approximately 3 more pills than those living in an urban area.  
Previous studies have focused on the odds of being prescribed a benzodiazepine; 
however, for this study, we wanted to examine further differences. Among males, those living in 
an urban area were prescribed approximately 1 milligram higher than those living in a rural area. 
Overall, those in urban area were prescribed a significantly higher drug strength on average than 
those in rural areas. It is important to note that this measurement, drug strength, does not account 
for different classes of benzodiazepines (long-acting compared to short-acting).  
 Using the diazepam equivalent, these measurements were standardized to a 5-milligram 
diazepam equivalent to allow for more accurate comparisons. After applying this standardization, 
the trends remained similar. Comparing rural and urban areas among males, those living in urban 
areas had a higher diazepam equivalent compared to those in rural areas (3.31 compared to 2.82 
5-mg diazepam equivalents). For individuals in the 45-64 age group, those in urban areas were 
prescribed a significantly higher number of diazepam equivalents compared to those in rural 
areas. Similar results were observed for those in the 25-44, 65-84 and 85+ age groups. Prior 
research has revealed that 14-23% of all prescriptions for elderly patients were inappropriate 
(Brekke et al., 2008). This demonstrates that individuals in an urban area are prescribing more 
benzodiazepines than those in a rural area (after transforming to a comparable metric), 
highlighting that prescribers/patients in an urban setting should be cognizant of potential for 
overprescribing. 
 An aggregate quantity was calculated, by multiplying the quantity of pills by the 5 mg 
diazepam equivalent. Individuals that were males, living in an urban area were prescribed 125-
5mg diazepam equivalents compared to 110 among males living in a rural area. Similarly, among 
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females, those living in an urban area were prescribed a higher number of 5mg diazepam 
equivalents compared to those living in a rural area. Overall, those living in urban areas were 
prescribed a significantly higher number of 5mg diazepam equivalents compared to those living 
in rural areas. Among those in the 65-84 age group, there was a significantly higher aggregate 
quantity prescribed to those living in urban areas compared to those in rural areas. Similar results 
were shown among the 25-44, 45-64 and 85+ age groups. Study findings highlight the 
importance of examining benzodiazepine prescribing across all ages since overprescribing can 
occur in groups other than seniors.  
5.2.4 Regression Analysis 
 Various guidelines have reported that benzodiazepines should be restricted to 30 days or 
less (Copperstock & Hill, 1982; APA, 1990; WHO, 1996; Katzman et al., 2014). For this study, 
an inappropriate prescription was defined as inappropriate if a new prescription was issued within 
30 days of the previous prescription ending.  
Results from the regression analyses demonstrated that the interaction of age and urban 
rural status is a significant predictor of inappropriate benzodiazepine prescribing regardless of the 
outcome being 30, 45 or 60 days. Manthey et al. (2011) conducted a multivariate analysis 
resulting in age being significantly associated with benzodiazepine usage, while Mattos et al. 
(2016) reported that age was not when using a multivariate binary logistic regression.  
 For total number of inappropriate prescriptions, regardless of the length of prescription in 
days, sex was statistically significant. When using the percentage of inappropriate prescriptions, 
sex was also statistically significant (p < 0.01), however it may not be clinically relevant due to 
high power of our study (as a function of the sample size of our study).  Mattos et al. (2016) 
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reported that the odds ratio was 1.71 for females to receive a benzodiazepine prescription, 
although this result was not statistically significant.  
 Overall, results from the linear regression show that males are more likely to have a lower 
number of inappropriate prescriptions compared to females. The current literature suggests that 
females and seniors, have an increased probability of receiving a benzodiazepine prescription, 
which aligns with some of the results from our study. While differences were observed for 
number of inappropriate prescriptions between male and females, while statistically significant, 
this may not be clinically relevant due to the large sample size. Differences were also observed 
among age groups when comparing individuals in urban and rural areas.  
5.2.5 Benzodiazepine Prescribing over a Ten-Year Period 
 Guidelines were updated in 2014 in Canada by Katzman et al. (2014), recommending that 
benzodiazepines be used only for short term durations (less than 30 days). In our study, dispensed 
days’ supply did not reduce over the ten-year period, although only three years were included 
subsequent to the updated guidelines.  
 Furthermore, aggregate quantity did not decrease over the timeframe examined. It was 
hypothesized that the rates of inappropriate prescribing would decrease after these guidelines 
were introduced. However, both the total number of inappropriate prescriptions and percentage of 
inappropriate prescriptions remained high (> 50%). Thus, inappropriate prescribing in this 
province is still high, despite updated guidelines. It is unknown why this is the case, nor what 
individual, practice or health system factors might be implicated in the overprescribing trends 
observed here. This highlights the need for interventions to change prescribing behavior. 
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Rigorously designed studies that measure prescribing pre and post intervention would be useful 
to examine the effectiveness of these methods.  
5.2.6 Benzodiazepine Use Compared to Canadian Provinces 
Rates of inappropriate prescribing and benzodiazepine usage were assessed in 
Newfoundland and Labrador for this study. Based upon duration, the results ranged from 72.7% 
to 74.9%.  
Cunningham et al. (2010) reported 3.5% of British Columbians used benzodiazepines 
long-term. A study conducted in Alberta, found 26.2% of individuals to have used 
benzodiazepines for a period of more than 121 days consecutively (Weir et al., 2018). In Ontario, 
Davies et al. (2018) reported that 73.5% of participants were prescribed more than one 
benzodiazepine in 2013. This study also reported a slight decrease in those prescribed more than 
one benzodiazepine between 1999 and 2013 from 74.2% to 73.5%.  
Canadian provinces were examined and compared in 2013 by Black et al. (2018), 
concluding that benzodiazepines were second-most prescribed in Newfoundland and Labrador 
(second only to New Brunswick). Comparing the results of these studies to our study, signifies 
that inappropriate prescribing remains high in Newfoundland compared to other provinces.  
5.3 Strengths and Limitations  
 
A ten-year time period was used for analyzing both prescriptions and usage allowing a 
longer observation of prescribing patterns than most studies, including three years after 
guidelines were introduced. Including all adult age groups allowed for inclusion of prescriptions 
that were typically underrepresented in previous studies, specifically the 18-24 age group. 
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Secondary data was used, which was initially collected for billing. Using this secondary data 
allowed for a large sample, 63,517 individuals, to be included in the analysis.  
A limitation of this study is the generalizability of the NLPDP to the general population. 
Due to the prescription drug coverage of the five programs comprising the NLPDP, the ability to 
apply these findings to the broader Newfoundland population may be limited. Seniors and those 
in low-income families may constitute a large proportion of the sample used in this study.  
 Another limitation of this study is the inability to distinguish between prescription and 
usage. We included only those that were “Settled-Paid;” when analyzing usage; however, an 
individual may have stopped using the medication due to adverse effects or not requiring it 
anymore. Furthermore, the definition used for overprescribing may overestimate the percentage 
of inappropriate prescriptions. Similarly, a limitation of this study is the prescriber data being 
classified in only two categories, GP or Other. Since individual prescriber information was not 
provided, it was not possible to assess broader prescriber effects.  
 Rural areas were defined based upon a population less than 1,000 (Statistics Canada, 
2017). Participants’ area codes were used to determine the place of residence, and a classification 
of urban or rural area. Community populations were determined using the 2011 census. A 
population with more than 1,000 people in 2007 could have more than 1,000 in 2017. The 2011 
Census was used for each year to account for these changes, but it remains a limitation. 
Furthermore, there are other definitions that could have been used such as those defined by the 
Newfoundland and Labrador Statistics Agency which may change the results of our analyses. If a 
larger population threshold was chosen, it would result in more rural areas than in our study.  
 When classifying prescriptions as being filled in an urban or rural area, an individual may 
have moved within a given fiscal year, particularly those in the more mobile younger age groups. 
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The data would not be updated until the beginning of the next fiscal year. Furthermore, there 
were no MCP files associated with the 2009, 2012 and 2013 fiscal years. As a result, the 
following year was used by the data custodian to determine the MCP number and the consequent 
urban / rural location.  
Dispensed days’ supply may have been estimated rather than an objective measurement. 
When a prescription was issued, physicians may have prescribed the medication as “take 1 tablet 
twice a day when needed”. Some individuals may have taken two pills a day, while others may 
have taken one pill every two days. Pharmacists inputting the days’ supply is an estimation of 
how long a quantity will last.  
5.4 Implications for Future Research and Practice  
 
 A large proportion of benzodiazepines are prescribed for inappropriate durations. 
Benzodiazepines are inappropriately prescribed at a high rate: in this study, > 70%. This finding 
strongly suggests the need for intervention, both in current medical training curricula and in 
continuing education programs. Prescribers should be encouraged to complete continuing 
education on the multitude of adverse effects associated with prolonged benzodiazepine usage. 
Furthermore, prescribers should be educated on risk factors for long-term benzodiazepine usage 
and updated on the recommended duration of two to four weeks. Even this, however, is not a 
guarantee that prescribing behavior will change, and carefully designed interventions will be 
needed to determine the predictors and mechanisms of behavior change.  
 General practitioners (GPs) were responsible for more than 96% of benzodiazepine 
prescriptions in this study. This is not surprising as GPs provide the bulk of primary care in this 
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jurisdiction. However, it suggests they should be the first group receiving additional educational 
interventions such as seminars, Continuing Medical Education and providing professional 
development credit for completing these. Ultimately, intervention research is urgently needed to 
test the most appropriate method of delivery and content of educational (or other) interventions 
aiming to reduce inappropriate usage of benzodiazepines.  
 There are a number of intervention methods available, including direct marketing and 
local opinion leader’s having an impact on professional behaviour change (Johnson & May, 
2015). Education interventions are another alternative, such as Choosing Wisely nationally, 
Deprescribing or SaferMedsNL locally (Choosing Wisely Canada, 2017; Canadian Deprescribing 
Network, 2017; SaferMedsNL, 2020). Ivers et al (2012) concluded that using audits and feedback 
lead to improvements in professional practice. Furthermore, there are financial incentive 
interventions, such as the French pay-for-performance; however, Rat et al. (2014) reported an 
increase in benzodiazepine prescribing between 2011 and 2012. These findings suggest there is 
not yet consensus on what intervention method is most effective for altering inappropriate 
benzodiazepine prescribing trends, and intervention research is urgently needed in this area.   
 Future research should also be conducted on national trends in benzodiazepine usage and 
the associated risk factors. Frequent adverse effects have been reported; however, the association 
between the gene affecting drug metabolism of benzodiazepines and associated adverse effects 
should be further explored. With the increasing availability of genome sequencing, this will be of 




5.5 Conclusion  
 
Benzodiazepines are believed to be one of the most overprescribed medications 
worldwide. The objective of this study was to examine the prescribing patterns of 
benzodiazepines among individuals, 18 years of age or older, living on the island of 
Newfoundland between 2007 and 2016. Using descriptive statistics, and regression analyses 
various metrics were calculated to assess the rate of overprescribing (based upon duration). 
Overprescribing was found to be prevalent throughout this time frame, with the implementation 
of guidelines ineffective at reducing benzodiazepine prescribing in this sample of Newfoundland 
adults. Inappropriate prescribing, specifically long-term use, has been associated with adverse 
effects including cognitive decline, falls, hip fracture in the elderly, tolerance and dementia. 
Close cooperation between policy makers, researchers, as well as prescribers and patients will be 
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Appendix 1: Year First Prescription was Written 
Year Frequency Percent 
2007 19,042 29.98 
2008 6,085 9.58 
2009 5,158 8.12 
2010 5,151 8.11 
2011 5,771 9.09 
2012 5,021 7.90 
2013 4,519 7.11 
2014 4,194 6.60 
2015 4,191 6.60 





















Appendix 3: Regression Diagnostic Graphs 
Inappropriate Prescriptions – 30 days definition 
 
Percentage of Inappropriate Prescriptions – 30 days 
 
 





















Number of Inappropriate Prescriptions – 30 days 
Before Removing Outliers 
 
Table 1 - Estimates Prior to Removing Outliers 
Variable Estimate Standard 
Error 
95% CI  P value1 
Intercept 3.92 0.122 3.69 to 4.16  
Sex     p < 0.05 
Female 
(ref) 
0    
Male 0.168 0.0705 0.0294 to 0.306  
Prescriber 
Specialty            
   p = 0.92 
GP 
(ref) 
0    
Other -0.0188 0.181 -0.374 to 0.336  
Age Group *  
Urban / Rural 
   p < 0.01 
Urban     
Age Group     
18 – 24 -0.0352 0.484 -0.983 to 0.913 p = 0.94 
25 – 44 0.873 0.351 0.185 to 1.56 p < 0.05 
45 - 64 1.44 0.325 0.798 to 2.07 p < 0.01 
65 - 84 0.143 0.311 -0.468 to 0.753 p = 0.65 
85+ 
(ref) 
0    
Rural     
Age Group     
18 - 24 0.0352 0.484 -0.913 to 0.983 p = 0.94 
25 - 44 -0.873 0.351 -1.56 to -0.185 p < 0.05 
45 - 64 -1.44 0.325 -2.07 to -0.798 p < 0.01 
65 - 84 -0.143 0.311 -0.753 to 0.468 p = 0.65 
85+ 
(ref) 








































After Removing Outliers 
 
Estimates After Removing Outliers 
Variable Estimate Standard 
Error 
95% CI  P value1 
Intercept 3.92 0.116 3.69 to 4.16  
Sex     p < 0.01 
Female 
(ref) 
0    
Male 0.193 0.0669 0.0615 to 0.324  
Prescriber 
Specialty            
   p = 0.98 
GP 
(ref) 
0    
Other -0.00354 0.172 -0.340 to 0.333  
Age Group *  
Urban / Rural 
   p < 0.01 
Urban     
Age Group     
18 – 24 -0.0377 0.459 -0.937 to 0.862 p = 0.93 
25 – 44 0.828 0.333 0.176 to 1.48 p < 0.05 
45 - 64 1.39 0.309 0.787 to 2.00 p < 0.01 
65 - 84 0.141 0.295 -0.437 to 0.720 p = 0.63 
85+ 
(ref) 
0    
Rural     
Age Group     
18 - 24 0.0377 0.459 -0.862 to 0.937 p = 0.93 
25 - 44 -0.828 0.333 -1.48 to -0.176 p < 0.05 
45 - 64 -1.39 0.309 -2.00 to -0.787 p < 0.01 
65 - 84 -0.141 0.295 -0.720 to 0.437 p = 0.63 
85+ 
(ref) 






































Inappropriate Prescriptions – 45 days definition 
 
Percentage of Inappropriate Prescriptions – 45 days 
 
 





































Number of Inappropriate Prescriptions – 45 days 
Before Removing Outliers 
 
Estimates Before Removing Outliers 
 
Variable Estimate Standard 
Error 
95% CI  P value1 
Intercept 4.03 0.124 3.79 to 4.27  
Sex     p < 0.05 
Female 
(ref) 
0    
Male 0.169 0.0716 0.0286 to 0.309  
Prescriber 
Specialty            
   p = 0.97 
GP 
(ref) 
0    
Other -0.00713 0.184 -0.368 to 0.354  
Age Group *  
Urban / Rural 
   p < 0.01 
Urban     
Age Group     
18 – 24 -0.0498 0.492 -1.01 to 0.914 p = 0.92 
25 – 44 0.889 0.357 0.190 to 1.59 p < 0.05 
45 - 64 1.46 0.331 0.812 to 2.11 p < 0.01 
65 - 84 0.135 0.316 -0.485 to 0.755 p = 0.67 
85+ 
(ref) 
0    
Rural     
Age Group     
18 - 24 0.0498 0.492 -0.914 to 1.01 p = 0.92 
25 - 44 -0.889 0.357 -1.59 to -0.190 p < 0.05 
45 - 64 -1.46 0.331 -2.11 to -0.812 p < 0.01 
65 - 84 -0.135 0.316 -0.755 to 0.485 p = 0.67 
85+ 
(ref) 








































After Removing Outliers 
 
Estimates After Removing Outliers 
 
Variable Estimate Standard 
Error 
95% CI  P value1 
Intercept 4.03 0.117 3.80 to 4.26  
Sex     p < 0.01 
Female 
(ref) 
0    
Male 0.195 0.0679 0.0617 to 0.328  
Prescriber 
Specialty            
   p = 0.96 
GP 
(ref) 
0    
Other 0.00864 0.174 -0.333 to 0.350  
Age Group *  
Urban / Rural 
   p < 0.01 
Urban     
Age Group     
18 – 24 -0.0525 0.466 -0.965 to 0.861 p = 0.91 
25 – 44 0.842 0.338 0.180 to 1.50 p < 0.05 
45 - 64 1.42 0.313 0.801 to 2.03 p < 0.01 
65 - 84 0.134 0.300 -0.454 to 0.722 p = 0.66 
85+ 
(ref) 
0    
Rural     
Age Group     
18 - 24 0.0525 0.466 -0.861 to 0.965 p = 0.91 
25 - 44 -0.842 0.338 -1.50 to -0.180 p < 0.05 
45 - 64 -1.42 0.313 -2.03 to -0.801 p < 0.01 
65 - 84 -0.134 0.300 -0.722 to 0.454 p = 0.66 
85+ 
(ref) 










































Inappropriate Prescriptions – 60 days definition 
 


























Number of Inappropriate Prescriptions – 60 days 
Before Removing Outliers 
 
Estimates Before Removing Outliers 
 
Variable Estimate Standard 
Error 
95% CI  P value1 
Intercept 4.14 0.126 3.89 to 4.38  
Sex     p < 0.05 
Female 
(ref) 
0    
Male 0.175 0.0727 0.0323 to 0.317  
Prescriber 
Specialty            
   p = 0.99 
GP 
(ref) 
0    
Other -0.00350 0.187 -0.369 to 0.362  
Age Group *  
Urban / Rural 
   p < 0.01 
Urban     
Age Group     
18 – 24 -0.0477 0.499 -1.03 to 0.930 p = 0.92 
25 – 44 0.897 0.362 0.188 to 1.61 p < 0.05 
45 - 64 1.50 0.336 0.839 to 2.15 p < 0.01 
65 - 84 0.145 0.321 -0.485 to 0.930 p = 0.65 
85+ 
(ref) 
0    
Rural     
Age Group     
18 - 24 0.0477 0.499 -0.930 to 1.03 p = 0.92 
25 - 44 -0.897 0.362 -1.61 to -0.188 p < 0.05 
45 - 64 -1.50 0.336 -2.15 to -0.839 p < 0.01 
65 - 84 -0.145 0.321 -0.774 to 0.485 p = 0.65 
85+ 
(ref) 








































After Removing Outliers 
 
Estimates After Removing Outliers 
 
Variable Estimate Standard 
Error 
95% CI  P value1 
Intercept 4.13 0.119 3.90 to 4.36  
Sex     p < 0.01 
Female 
(ref) 
0    
Male 0.201 0.0688 0.0662 to 0.336  
Prescriber 
Specialty            
   p = 0.94 
GP 
(ref) 
0    
Other 0.0127 0.177 -0.334 to 0.359  
Age Group *  
Urban / Rural 
   p < 0.01 
Urban     
Age Group     
18 – 24 -0.0504 0.472 -0.976 to 0.875 p = 0.92 
25 – 44 0.849 0.342 0.178 to 1.52 p < 0.05 
45 - 64 1.45 0.318 0.829 to 2.07 p < 0.01 
65 - 84 0.143 0.304 -0.452 to 0.739 p = 0.64 
85+ 
(ref) 
0    
Rural     
Age Group     
18 - 24 0.0504 0.472 -0.875 to 0.976 p = 0.92 
25 - 44 -0.849 0.342 -1.52 to -0.178 p < 0.05 
45 - 64 -1.45 0.318 -2.07 to -0.829 p < 0.01 
65 - 84 -0.143 0.304 -0.739 to 0.452 p = 0.64 
85+ 
(ref) 




































Appendix 4: SAS Program and Output 
Percentage of Inappropriate Prescriptions (30 days definition) 
 
proc genmod data=percent-inapp-30days; 
class Sex(ref="F") UrbanRuralStatus Age-Group 
PrescriberSpeciality(ref='GP')/param=ref; 
model percent-inapp = Age-Group Sex UrbanRuralStatus PrescriberSpeciality 
 UrbanRuralStatus*Age-Group / dist=normal link=identity type3; 
Estimate “M vs F” Sex 1 -1; 
Estimate “Other vs GP” PrescriberSpeciality 1 -1; 
Estimate “Urban: Age-Group=1 vs Age-Group=5” Age-Group 1 0 0 0 -1 UrbanRuralStatus*Age-
Group 0 0 0 0 0 1 0 0 0 -1; 
Estimate “Urban: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 1 0 0 -1; 
Estimate “Urban: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 1 0 -1; 
Estimate “Urban: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 0 1 -1; 
Estimate “Rural: Age-Group =1 vs Age-Group =5” Age-Group 1 0 0 0 -1 UrbanRuralStatus* 
Age-Group 1 0 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 1 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 1 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 

























Number of Observations Read 63517
Number of Observations Used 63517
Class Level Information





Age_Group 1 1 0 0 0
2 0 1 0 0
3 0 0 1 0
4 0 0 0 1













Prm9 UrbanRural*Age_Group Rural 1
Prm10 UrbanRural*Age_Group Rural 2
Prm11 UrbanRural*Age_Group Rural 3
Prm12 UrbanRural*Age_Group Rural 4
Monday, 26 April, 2021 12:53:01 PM 2
The GENMOD Procedure
Criteria For Assessing Goodness Of Fit
Criterion DF Value Value/DF
Deviance 64E3 7267.1161 0.1144
Scaled Deviance 64E3 63517.0000 1.0002
Pearson Chi-Square 64E3 7267.1161 0.1144
Scaled Pearson X2 64E3 63517.0000 1.0002
Log Likelihood -21275.9403
Full Log Likelihood -21275.9403
AIC (smaller is better) 42577.8806
AICC (smaller is better) 42577.8863
BIC (smaller is better) 42695.6484
Algorithm converged.








Chi-Square Pr > ChiSq
Intercept 1 0.4150 0.0048 0.4055 0.4244 7391.44 <.0001
Age_Group 1 1 -0.1983 0.0080 -0.2140 -0.1825 608.94 <.0001
Age_Group 2 1 -0.1122 0.0058 -0.1237 -0.1008 368.87 <.0001
Age_Group 3 1 -0.0401 0.0057 -0.0512 -0.0291 50.40 <.0001
Age_Group 4 1 -0.0324 0.0054 -0.0430 -0.0218 35.84 <.0001
Sex M 1 0.0091 0.0028 0.0036 0.0146 10.65 0.0011
UrbanRuralStatus Rural 1 -0.0205 0.0113 -0.0427 0.0017 3.26 0.0709
PrescriberSpeciality Other 1 -0.0110 0.0072 -0.0251 0.0030 2.36 0.1244
UrbanRural*Age_Group Rural 1 1 -0.0293 0.0192 -0.0668 0.0083 2.33 0.1270
UrbanRural*Age_Group Rural 2 1 -0.0351 0.0139 -0.0623 -0.0078 6.36 0.0117
UrbanRural*Age_Group Rural 3 1 -0.0441 0.0129 -0.0694 -0.0188 11.69 0.0006
UrbanRural*Age_Group Rural 4 1 -0.0127 0.0123 -0.0369 0.0115 1.05 0.3049
Scale 1 0.3382 0.0009 0.3364 0.3401
Note: The scale parameter was estimated by maximum likelihood.
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
Age_Group 4 1014.90 <.0001
Sex 1 10.65 0.0011
UrbanRuralStatus 1 3.26 0.0709
Monday, 26 April, 2021 12:53:01 PM 3
The GENMOD Procedure
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
PrescriberSpeciality 1 2.36 0.1244
UrbanRural*Age_Group 4 22.54 0.0002
Note: Under full-rank parameterizations, Type 3 effect tests are replaced by joint tests. The joint test for an effect is a test that all the parameters associated with that













Limits Chi-Square Pr > ChiSq
M vs F -0.0091 -0.0146 -0.0036 -0.0091 0.0028 0.05 -0.0146 -0.0036 10.65 0.0011
Other vs GP -0.0110 -0.0251 0.0030 -0.0110 0.0072 0.05 -0.0251 0.0030 2.36 0.1244
Urban: Age-Group=1 vs Age-Group=5 -0.1983 -0.2140 -0.1825 -0.1983 0.0080 0.05 -0.2140 -0.1825 608.94 <.0001
Urban: Age-Group =2 vs Age-Group =5 -0.1122 -0.1237 -0.1008 -0.1122 0.0058 0.05 -0.1237 -0.1008 368.87 <.0001
Urban: Age-Group =3 vs Age-Group =5 -0.0401 -0.0512 -0.0291 -0.0401 0.0057 0.05 -0.0512 -0.0291 50.40 <.0001
Urban: Age-Group =4 vs Age-Group =5 -0.0324 -0.0430 -0.0218 -0.0324 0.0054 0.05 -0.0430 -0.0218 35.84 <.0001
Rural: Age-Group =1 vs Age-Group =5 -0.2275 -0.2617 -0.1934 -0.2275 0.0174 0.05 -0.2617 -0.1934 170.66 <.0001
Rural: Age-Group =2 vs Age-Group =5 -0.1473 -0.1720 -0.1226 -0.1473 0.0126 0.05 -0.1720 -0.1226 136.17 <.0001
Rural: Age-Group =3 vs Age-Group =5 -0.0842 -0.1070 -0.0615 -0.0842 0.0116 0.05 -0.1070 -0.0615 52.69 <.0001
Rural: Age-Group =4 vs Age-Group =5 -0.0450 -0.0668 -0.0233 -0.0450 0.0111 0.05 -0.0668 -0.0233 16.44 <.0001
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Number of Inappropriate Prescriptions (30 days definition) 
 
proc genmod data = number-inapp-30days; 
class Sex(ref="F") UrbanRuralStatus Age-Group 
PrescriberSpeciality(ref='GP')/param=ref; 
model num-inapp = Age-Group Sex UrbanRuralStatus PrescriberSpeciality 
 UrbanRuralStatus*Age-Group / dist=normal link=identity type3; 
Estimate “M vs F” Sex 1 -1; 
Estimate “Other vs GP” PrescriberSpeciality 1 -1; 
Estimate “Urban: Age-Group=1 vs Age-Group=5” Age-Group 1 0 0 0 -1 UrbanRuralStatus*Age-
Group 0 0 0 0 0 1 0 0 0 -1; 
Estimate “Urban: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 1 0 0 -1; 
Estimate “Urban: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 1 0 -1; 
Estimate “Urban: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 0 1 -1; 
Estimate “Rural: Age-Group =1 vs Age-Group =5” Age-Group 1 0 0 0 -1 UrbanRuralStatus* 
Age-Group 1 0 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 1 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 1 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
























Number of Observations Read 63517
Number of Observations Used 63517
Class Level Information





Age_Group 1 1 0 0 0
2 0 1 0 0
3 0 0 1 0
4 0 0 0 1













Prm9 UrbanRural*Age_Group Rural 1
Prm10 UrbanRural*Age_Group Rural 2
Prm11 UrbanRural*Age_Group Rural 3
Prm12 UrbanRural*Age_Group Rural 4
Monday, 26 April, 2021 12:56:56 PM 2
The GENMOD Procedure
Criteria For Assessing Goodness Of Fit
Criterion DF Value Value/DF
Deviance 64E3 4624608.5155 72.8227
Scaled Deviance 64E3 63517.0000 1.0002
Pearson Chi-Square 64E3 4624608.5155 72.8227
Scaled Pearson X2 64E3 63517.0000 1.0002
Log Likelihood -226302.0669
Full Log Likelihood -226302.0669
AIC (smaller is better) 452630.1337
AICC (smaller is better) 452630.1394
BIC (smaller is better) 452747.9015
Algorithm converged.








Chi-Square Pr > ChiSq
Intercept 1 3.9245 0.1218 3.6859 4.1632 1038.82 <.0001
Age_Group 1 1 -2.2553 0.2027 -2.6526 -1.8580 123.80 <.0001
Age_Group 2 1 -0.2556 0.1474 -0.5446 0.0333 3.01 0.0829
Age_Group 3 1 1.0607 0.1426 0.7812 1.3402 55.32 <.0001
Age_Group 4 1 -0.2045 0.1364 -0.4718 0.0628 2.25 0.1338
Sex M 1 0.1675 0.0705 0.0294 0.3057 5.65 0.0175
UrbanRuralStatus Rural 1 -0.4279 0.2861 -0.9886 0.1329 2.24 0.1348
PrescriberSpeciality Other 1 -0.0188 0.1811 -0.3737 0.3361 0.01 0.9172
UrbanRural*Age_Group Rural 1 1 0.0352 0.4838 -0.9130 0.9834 0.01 0.9420
UrbanRural*Age_Group Rural 2 1 -0.8727 0.3508 -1.5603 -0.1851 6.19 0.0129
UrbanRural*Age_Group Rural 3 1 -1.4354 0.3254 -2.0733 -0.7976 19.45 <.0001
UrbanRural*Age_Group Rural 4 1 -0.1427 0.3113 -0.7529 0.4676 0.21 0.6468
Scale 1 8.5328 0.0239 8.4860 8.5799
Note: The scale parameter was estimated by maximum likelihood.
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
Age_Group 4 408.78 <.0001
Sex 1 5.65 0.0175
UrbanRuralStatus 1 2.24 0.1348
Monday, 26 April, 2021 12:56:56 PM 3
The GENMOD Procedure
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
PrescriberSpeciality 1 0.01 0.9172
UrbanRural*Age_Group 4 51.68 <.0001
Note: Under full-rank parameterizations, Type 3 effect tests are replaced by joint tests. The joint test for an effect is a test that all the parameters associated with that













Limits Chi-Square Pr > ChiSq
M vs F -0.1675 -0.3057 -0.0294 -0.1675 0.0705 0.05 -0.3057 -0.0294 5.65 0.0175
Other vs GP -0.0188 -0.3737 0.3361 -0.0188 0.1811 0.05 -0.3737 0.3361 0.01 0.9172
Urban: Age-Group=1 vs Age-Group=5 -2.2553 -2.6526 -1.8580 -2.2553 0.2027 0.05 -2.6526 -1.8580 123.80 <.0001
Urban: Age-Group =2 vs Age-Group =5 -0.2556 -0.5446 0.0333 -0.2556 0.1474 0.05 -0.5446 0.0333 3.01 0.0829
Urban: Age-Group =3 vs Age-Group =5 1.0607 0.7812 1.3402 1.0607 0.1426 0.05 0.7812 1.3402 55.32 <.0001
Urban: Age-Group =4 vs Age-Group =5 -0.2045 -0.4718 0.0628 -0.2045 0.1364 0.05 -0.4718 0.0628 2.25 0.1338
Rural: Age-Group =1 vs Age-Group =5 -2.2201 -3.0813 -1.3589 -2.2201 0.4394 0.05 -3.0813 -1.3589 25.53 <.0001
Rural: Age-Group =2 vs Age-Group =5 -1.1284 -1.7524 -0.5043 -1.1284 0.3184 0.05 -1.7524 -0.5043 12.56 0.0004
Rural: Age-Group =3 vs Age-Group =5 -0.3747 -0.9485 0.1991 -0.3747 0.2928 0.05 -0.9485 0.1991 1.64 0.2005
Rural: Age-Group =4 vs Age-Group =5 -0.3471 -0.8962 0.2019 -0.3471 0.2802 0.05 -0.8962 0.2019 1.54 0.2153
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Percentage of Inappropriate Prescriptions (45 days definition) 
 
proc genmod data=percent-inapp-30days; 
class Sex(ref="F") UrbanRuralStatus Age-Group 
PrescriberSpeciality(ref='GP')/param=ref; 
model percent-inapp = Age-Group Sex UrbanRuralStatus PrescriberSpeciality 
 UrbanRuralStatus*Age-Group / dist=normal link=identity type3; 
Estimate “M vs F” Sex 1 -1; 
Estimate “Other vs GP” PrescriberSpeciality 1 -1; 
Estimate “Urban: Age-Group=1 vs Age-Group=5” Age-Group 1 0 0 0 -1 UrbanRuralStatus*Age-
Group 0 0 0 0 0 1 0 0 0 -1; 
Estimate “Urban: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 1 0 0 -1; 
Estimate “Urban: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 1 0 -1; 
Estimate “Urban: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 0 1 -1; 
Estimate “Rural: Age-Group =1 vs Age-Group =5” Age-Group 1 0 0 0 -1 UrbanRuralStatus* 
Age-Group 1 0 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 1 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 1 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 

























Number of Observations Read 63517
Number of Observations Used 63517
Class Level Information





Age_Group 1 1 0 0 0
2 0 1 0 0
3 0 0 1 0
4 0 0 0 1













Prm9 UrbanRural*Age_Group Rural 1
Prm10 UrbanRural*Age_Group Rural 2
Prm11 UrbanRural*Age_Group Rural 3
Prm12 UrbanRural*Age_Group Rural 4
Monday, 26 April, 2021 01:00:07 PM 2
The GENMOD Procedure
Criteria For Assessing Goodness Of Fit
Criterion DF Value Value/DF
Deviance 64E3 7498.3076 0.1181
Scaled Deviance 64E3 63517.0000 1.0002
Pearson Chi-Square 64E3 7498.3076 0.1181
Scaled Pearson X2 64E3 63517.0000 1.0002
Log Likelihood -22270.5470
Full Log Likelihood -22270.5470
AIC (smaller is better) 44567.0940
AICC (smaller is better) 44567.0997
BIC (smaller is better) 44684.8618
Algorithm converged.








Chi-Square Pr > ChiSq
Intercept 1 0.4300 0.0049 0.4204 0.4396 7690.69 <.0001
Age_Group 1 1 -0.2059 0.0082 -0.2219 -0.1899 636.41 <.0001
Age_Group 2 1 -0.1160 0.0059 -0.1277 -0.1044 382.08 <.0001
Age_Group 3 1 -0.0403 0.0057 -0.0516 -0.0291 49.34 <.0001
Age_Group 4 1 -0.0341 0.0055 -0.0448 -0.0233 38.49 <.0001
Sex M 1 0.0091 0.0028 0.0036 0.0147 10.32 0.0013
UrbanRuralStatus Rural 1 -0.0200 0.0115 -0.0426 0.0026 3.01 0.0827
PrescriberSpeciality Other 1 -0.0109 0.0073 -0.0252 0.0034 2.24 0.1342
UrbanRural*Age_Group Rural 1 1 -0.0293 0.0195 -0.0675 0.0089 2.27 0.1322
UrbanRural*Age_Group Rural 2 1 -0.0372 0.0141 -0.0649 -0.0095 6.94 0.0084
UrbanRural*Age_Group Rural 3 1 -0.0464 0.0131 -0.0721 -0.0207 12.52 0.0004
UrbanRural*Age_Group Rural 4 1 -0.0147 0.0125 -0.0393 0.0098 1.38 0.2400
Scale 1 0.3436 0.0010 0.3417 0.3455
Note: The scale parameter was estimated by maximum likelihood.
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
Age_Group 4 1056.90 <.0001
Sex 1 10.32 0.0013
UrbanRuralStatus 1 3.01 0.0827
Monday, 26 April, 2021 01:00:07 PM 3
The GENMOD Procedure
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
PrescriberSpeciality 1 2.24 0.1342
UrbanRural*Age_Group 4 22.82 0.0001
Note: Under full-rank parameterizations, Type 3 effect tests are replaced by joint tests. The joint test for an effect is a test that all the parameters associated with that













Limits Chi-Square Pr > ChiSq
M vs F -0.0091 -0.0147 -0.0036 -0.0091 0.0028 0.05 -0.0147 -0.0036 10.32 0.0013
Other vs GP -0.0109 -0.0252 0.0034 -0.0109 0.0073 0.05 -0.0252 0.0034 2.24 0.1342
Urban: Age-Group=1 vs Age-Group=5 -0.2059 -0.2219 -0.1899 -0.2059 0.0082 0.05 -0.2219 -0.1899 636.41 <.0001
Urban: Age-Group =2 vs Age-Group =5 -0.1160 -0.1277 -0.1044 -0.1160 0.0059 0.05 -0.1277 -0.1044 382.08 <.0001
Urban: Age-Group =3 vs Age-Group =5 -0.0403 -0.0516 -0.0291 -0.0403 0.0057 0.05 -0.0516 -0.0291 49.34 <.0001
Urban: Age-Group =4 vs Age-Group =5 -0.0341 -0.0448 -0.0233 -0.0341 0.0055 0.05 -0.0448 -0.0233 38.49 <.0001
Rural: Age-Group =1 vs Age-Group =5 -0.2352 -0.2699 -0.2006 -0.2352 0.0177 0.05 -0.2699 -0.2006 176.76 <.0001
Rural: Age-Group =2 vs Age-Group =5 -0.1532 -0.1784 -0.1281 -0.1532 0.0128 0.05 -0.1784 -0.1281 142.84 <.0001
Rural: Age-Group =3 vs Age-Group =5 -0.0867 -0.1098 -0.0636 -0.0867 0.0118 0.05 -0.1098 -0.0636 54.11 <.0001
Rural: Age-Group =4 vs Age-Group =5 -0.0488 -0.0709 -0.0267 -0.0488 0.0113 0.05 -0.0709 -0.0267 18.71 <.0001
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Number of Inappropriate Prescriptions (45 days definition) 
 
proc genmod data = number-inapp-30days; 
class Sex(ref="F") UrbanRuralStatus Age-Group 
PrescriberSpeciality(ref='GP')/param=ref; 
model num-inapp = Age-Group Sex UrbanRuralStatus PrescriberSpeciality 
 UrbanRuralStatus*Age-Group / dist=normal link=identity type3; 
Estimate “M vs F” Sex 1 -1; 
Estimate “Other vs GP” PrescriberSpeciality 1 -1; 
Estimate “Urban: Age-Group=1 vs Age-Group=5” Age-Group 1 0 0 0 -1 UrbanRuralStatus*Age-
Group 0 0 0 0 0 1 0 0 0 -1; 
Estimate “Urban: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 1 0 0 -1; 
Estimate “Urban: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 1 0 -1; 
Estimate “Urban: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 0 1 -1; 
Estimate “Rural: Age-Group =1 vs Age-Group =5” Age-Group 1 0 0 0 -1 UrbanRuralStatus* 
Age-Group 1 0 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 1 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 1 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 


























Number of Observations Read 63517
Number of Observations Used 63517
Class Level Information





Age_Group 1 1 0 0 0
2 0 1 0 0
3 0 0 1 0
4 0 0 0 1













Prm9 UrbanRural*Age_Group Rural 1
Prm10 UrbanRural*Age_Group Rural 2
Prm11 UrbanRural*Age_Group Rural 3
Prm12 UrbanRural*Age_Group Rural 4
Monday, 26 April, 2021 01:00:28 PM 2
The GENMOD Procedure
Criteria For Assessing Goodness Of Fit
Criterion DF Value Value/DF
Deviance 64E3 4774975.9454 75.1906
Scaled Deviance 64E3 63517.0000 1.0002
Pearson Chi-Square 64E3 4774975.9454 75.1906
Scaled Pearson X2 64E3 63517.0000 1.0002
Log Likelihood -227318.2504
Full Log Likelihood -227318.2504
AIC (smaller is better) 454662.5008
AICC (smaller is better) 454662.5065
BIC (smaller is better) 454780.2686
Algorithm converged.








Chi-Square Pr > ChiSq
Intercept 1 4.0320 0.1237 3.7895 4.2745 1061.94 <.0001
Age_Group 1 1 -2.3150 0.2060 -2.7187 -1.9113 126.33 <.0001
Age_Group 2 1 -0.2701 0.1498 -0.5636 0.0235 3.25 0.0714
Age_Group 3 1 1.0977 0.1449 0.8137 1.3818 57.39 <.0001
Age_Group 4 1 -0.2156 0.1386 -0.4873 0.0560 2.42 0.1197
Sex M 1 0.1690 0.0716 0.0286 0.3094 5.57 0.0183
UrbanRuralStatus Rural 1 -0.4467 0.2907 -1.0165 0.1231 2.36 0.1244
PrescriberSpeciality Other 1 -0.0071 0.1840 -0.3678 0.3535 0.00 0.9691
UrbanRural*Age_Group Rural 1 1 0.0498 0.4916 -0.9136 1.0133 0.01 0.9193
UrbanRural*Age_Group Rural 2 1 -0.8886 0.3565 -1.5873 -0.1899 6.21 0.0127
UrbanRural*Age_Group Rural 3 1 -1.4599 0.3307 -2.1080 -0.8117 19.49 <.0001
UrbanRural*Age_Group Rural 4 1 -0.1352 0.3164 -0.7553 0.4849 0.18 0.6691
Scale 1 8.6704 0.0243 8.6229 8.7182
Note: The scale parameter was estimated by maximum likelihood.
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
Age_Group 4 421.63 <.0001
Sex 1 5.57 0.0183
UrbanRuralStatus 1 2.36 0.1244
Monday, 26 April, 2021 01:00:28 PM 3
The GENMOD Procedure
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
PrescriberSpeciality 1 0.00 0.9691
UrbanRural*Age_Group 4 52.49 <.0001
Note: Under full-rank parameterizations, Type 3 effect tests are replaced by joint tests. The joint test for an effect is a test that all the parameters associated with that













Limits Chi-Square Pr > ChiSq
M vs F -0.1690 -0.3094 -0.0286 -0.1690 0.0716 0.05 -0.3094 -0.0286 5.57 0.0183
Other vs GP -0.0071 -0.3678 0.3535 -0.0071 0.1840 0.05 -0.3678 0.3535 0.00 0.9691
Urban: Age-Group=1 vs Age-Group=5 -2.3150 -2.7187 -1.9113 -2.3150 0.2060 0.05 -2.7187 -1.9113 126.33 <.0001
Urban: Age-Group =2 vs Age-Group =5 -0.2701 -0.5636 0.0235 -0.2701 0.1498 0.05 -0.5636 0.0235 3.25 0.0714
Urban: Age-Group =3 vs Age-Group =5 1.0977 0.8137 1.3818 1.0977 0.1449 0.05 0.8137 1.3818 57.39 <.0001
Urban: Age-Group =4 vs Age-Group =5 -0.2156 -0.4873 0.0560 -0.2156 0.1386 0.05 -0.4873 0.0560 2.42 0.1197
Rural: Age-Group =1 vs Age-Group =5 -2.2652 -3.1403 -1.3901 -2.2652 0.4465 0.05 -3.1403 -1.3901 25.74 <.0001
Rural: Age-Group =2 vs Age-Group =5 -1.1587 -1.7928 -0.5246 -1.1587 0.3235 0.05 -1.7928 -0.5246 12.83 0.0003
Rural: Age-Group =3 vs Age-Group =5 -0.3621 -0.9452 0.2209 -0.3621 0.2975 0.05 -0.9452 0.2209 1.48 0.2235
Rural: Age-Group =4 vs Age-Group =5 -0.3508 -0.9088 0.2071 -0.3508 0.2847 0.05 -0.9088 0.2071 1.52 0.2178
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Percentage of Inappropriate Prescriptions (60 days definition) 
 
proc genmod data=percent-inapp-30days; 
class Sex(ref="F") UrbanRuralStatus Age-Group 
PrescriberSpeciality(ref='GP')/param=ref; 
model percent-inapp = Age-Group Sex UrbanRuralStatus PrescriberSpeciality 
 UrbanRuralStatus*Age-Group / dist=normal link=identity type3; 
Estimate “M vs F” Sex 1 -1; 
Estimate “Other vs GP” PrescriberSpeciality 1 -1; 
Estimate “Urban: Age-Group=1 vs Age-Group=5” Age-Group 1 0 0 0 -1 UrbanRuralStatus*Age-
Group 0 0 0 0 0 1 0 0 0 -1; 
Estimate “Urban: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 1 0 0 -1; 
Estimate “Urban: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 1 0 -1; 
Estimate “Urban: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 0 1 -1; 
Estimate “Rural: Age-Group =1 vs Age-Group =5” Age-Group 1 0 0 0 -1 UrbanRuralStatus* 
Age-Group 1 0 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 1 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 1 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 

























Number of Observations Read 63517
Number of Observations Used 63517
Class Level Information





Age_Group 1 1 0 0 0
2 0 1 0 0
3 0 0 1 0
4 0 0 0 1













Prm9 UrbanRural*Age_Group Rural 1
Prm10 UrbanRural*Age_Group Rural 2
Prm11 UrbanRural*Age_Group Rural 3
Prm12 UrbanRural*Age_Group Rural 4
Monday, 26 April, 2021 01:01:44 PM 2
The GENMOD Procedure
Criteria For Assessing Goodness Of Fit
Criterion DF Value Value/DF
Deviance 64E3 7705.2809 0.1213
Scaled Deviance 64E3 63517.0000 1.0002
Pearson Chi-Square 64E3 7705.2809 0.1213
Scaled Pearson X2 64E3 63517.0000 1.0002
Log Likelihood -23135.2862
Full Log Likelihood -23135.2862
AIC (smaller is better) 46296.5725
AICC (smaller is better) 46296.5782
BIC (smaller is better) 46414.3403
Algorithm converged.








Chi-Square Pr > ChiSq
Intercept 1 0.4432 0.0050 0.4335 0.4530 7952.52 <.0001
Age_Group 1 1 -0.2109 0.0083 -0.2271 -0.1947 649.76 <.0001
Age_Group 2 1 -0.1203 0.0060 -0.1321 -0.1085 399.96 <.0001
Age_Group 3 1 -0.0421 0.0058 -0.0535 -0.0307 52.24 <.0001
Age_Group 4 1 -0.0358 0.0056 -0.0467 -0.0249 41.34 <.0001
Sex M 1 0.0093 0.0029 0.0037 0.0149 10.46 0.0012
UrbanRuralStatus Rural 1 -0.0205 0.0117 -0.0433 0.0024 3.07 0.0798
PrescriberSpeciality Other 1 -0.0118 0.0074 -0.0263 0.0027 2.56 0.1095
UrbanRural*Age_Group Rural 1 1 -0.0312 0.0197 -0.0699 0.0075 2.50 0.1138
UrbanRural*Age_Group Rural 2 1 -0.0370 0.0143 -0.0651 -0.0090 6.68 0.0097
UrbanRural*Age_Group Rural 3 1 -0.0480 0.0133 -0.0741 -0.0220 13.08 0.0003
UrbanRural*Age_Group Rural 4 1 -0.0161 0.0127 -0.0410 0.0088 1.61 0.2052
Scale 1 0.3483 0.0010 0.3464 0.3502
Note: The scale parameter was estimated by maximum likelihood.
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
Age_Group 4 1083.68 <.0001
Sex 1 10.46 0.0012
UrbanRuralStatus 1 3.07 0.0798
Monday, 26 April, 2021 01:01:44 PM 3
The GENMOD Procedure
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
PrescriberSpeciality 1 2.56 0.1095
UrbanRural*Age_Group 4 22.59 0.0002
Note: Under full-rank parameterizations, Type 3 effect tests are replaced by joint tests. The joint test for an effect is a test that all the parameters associated with that













Limits Chi-Square Pr > ChiSq
M vs F -0.0093 -0.0149 -0.0037 -0.0093 0.0029 0.05 -0.0149 -0.0037 10.46 0.0012
Other vs GP -0.0118 -0.0263 0.0027 -0.0118 0.0074 0.05 -0.0263 0.0027 2.56 0.1095
Urban: Age-Group=1 vs Age-Group=5 -0.2109 -0.2271 -0.1947 -0.2109 0.0083 0.05 -0.2271 -0.1947 649.76 <.0001
Urban: Age-Group =2 vs Age-Group =5 -0.1203 -0.1321 -0.1085 -0.1203 0.0060 0.05 -0.1321 -0.1085 399.96 <.0001
Urban: Age-Group =3 vs Age-Group =5 -0.0421 -0.0535 -0.0307 -0.0421 0.0058 0.05 -0.0535 -0.0307 52.24 <.0001
Urban: Age-Group =4 vs Age-Group =5 -0.0358 -0.0467 -0.0249 -0.0358 0.0056 0.05 -0.0467 -0.0249 41.34 <.0001
Rural: Age-Group =1 vs Age-Group =5 -0.2421 -0.2773 -0.2070 -0.2421 0.0179 0.05 -0.2773 -0.2070 182.25 <.0001
Rural: Age-Group =2 vs Age-Group =5 -0.1574 -0.1828 -0.1319 -0.1574 0.0130 0.05 -0.1828 -0.1319 146.58 <.0001
Rural: Age-Group =3 vs Age-Group =5 -0.0901 -0.1135 -0.0667 -0.0901 0.0119 0.05 -0.1135 -0.0667 56.86 <.0001
Rural: Age-Group =4 vs Age-Group =5 -0.0519 -0.0743 -0.0295 -0.0519 0.0114 0.05 -0.0743 -0.0295 20.59 <.0001
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Number of Inappropriate Prescriptions (60 days definition) 
 
proc genmod data = number-inapp-30days; 
class Sex(ref="F") UrbanRuralStatus Age-Group 
PrescriberSpeciality(ref='GP')/param=ref; 
model num-inapp = Age-Group Sex UrbanRuralStatus PrescriberSpeciality 
 UrbanRuralStatus*Age-Group / dist=normal link=identity type3; 
Estimate “M vs F” Sex 1 -1; 
Estimate “Other vs GP” PrescriberSpeciality 1 -1; 
Estimate “Urban: Age-Group=1 vs Age-Group=5” Age-Group 1 0 0 0 -1 UrbanRuralStatus*Age-
Group 0 0 0 0 0 1 0 0 0 -1; 
Estimate “Urban: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 1 0 0 -1; 
Estimate “Urban: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 1 0 -1; 
Estimate “Urban: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
Age-Group 0 0 0 0 0 0 0 0 1 -1; 
Estimate “Rural: Age-Group =1 vs Age-Group =5” Age-Group 1 0 0 0 -1 UrbanRuralStatus* 
Age-Group 1 0 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =2 vs Age-Group =5” Age-Group 0 1 0 0 -1 UrbanRuralStatus* 
Age-Group 0 1 0 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =3 vs Age-Group =5” Age-Group 0 0 1 0 -1 UrbanRuralStatus* 
Age-Group 0 0 1 0 -1 0 0 0 0 0; 
Estimate “Rural: Age-Group =4 vs Age-Group =5” Age-Group 0 0 0 1 -1 UrbanRuralStatus* 
Age-Group 0 0 0 1 -1 0 0 0 0 0; 
run; 
 







Number of Observations Read 63517
Number of Observations Used 63517
Class Level Information





Age_Group 1 1 0 0 0
2 0 1 0 0
3 0 0 1 0
4 0 0 0 1













Prm9 UrbanRural*Age_Group Rural 1
Prm10 UrbanRural*Age_Group Rural 2
Prm11 UrbanRural*Age_Group Rural 3
Prm12 UrbanRural*Age_Group Rural 4
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The GENMOD Procedure
Criteria For Assessing Goodness Of Fit
Criterion DF Value Value/DF
Deviance 64E3 4914480.3677 77.3873
Scaled Deviance 64E3 63517.0000 1.0002
Pearson Chi-Square 64E3 4914480.3677 77.3873
Scaled Pearson X2 64E3 63517.0000 1.0002
Log Likelihood -228232.8027
Full Log Likelihood -228232.8027
AIC (smaller is better) 456491.6054
AICC (smaller is better) 456491.6111
BIC (smaller is better) 456609.3732
Algorithm converged.








Chi-Square Pr > ChiSq
Intercept 1 4.1383 0.1255 3.8922 4.3843 1086.92 <.0001
Age_Group 1 1 -2.3809 0.2090 -2.7905 -1.9714 129.83 <.0001
Age_Group 2 1 -0.3044 0.1520 -0.6022 -0.0066 4.01 0.0451
Age_Group 3 1 1.1043 0.1470 0.8162 1.3924 56.43 <.0001
Age_Group 4 1 -0.2372 0.1406 -0.5128 0.0384 2.85 0.0916
Sex M 1 0.1747 0.0727 0.0323 0.3171 5.78 0.0162
UrbanRuralStatus Rural 1 -0.4579 0.2949 -1.0359 0.1202 2.41 0.1206
PrescriberSpeciality Other 1 -0.0035 0.1867 -0.3694 0.3624 0.00 0.9851
UrbanRural*Age_Group Rural 1 1 0.0477 0.4987 -0.9298 1.0251 0.01 0.9239
UrbanRural*Age_Group Rural 2 1 -0.8967 0.3616 -1.6055 -0.1879 6.15 0.0132
UrbanRural*Age_Group Rural 3 1 -1.4967 0.3355 -2.1542 -0.8392 19.90 <.0001
UrbanRural*Age_Group Rural 4 1 -0.1445 0.3210 -0.7736 0.4845 0.20 0.6525
Scale 1 8.7962 0.0247 8.7479 8.8447
Note: The scale parameter was estimated by maximum likelihood.
LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
Age_Group 4 428.17 <.0001
Sex 1 5.78 0.0162
UrbanRuralStatus 1 2.41 0.1206
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LR Statistics For Joint Tests
Source DF Chi-Square Pr > ChiSq
PrescriberSpeciality 1 0.00 0.9851
UrbanRural*Age_Group 4 53.04 <.0001
Note: Under full-rank parameterizations, Type 3 effect tests are replaced by joint tests. The joint test for an effect is a test that all the parameters associated with that













Limits Chi-Square Pr > ChiSq
M vs F -0.1747 -0.3171 -0.0323 -0.1747 0.0727 0.05 -0.3171 -0.0323 5.78 0.0162
Other vs GP -0.0035 -0.3694 0.3624 -0.0035 0.1867 0.05 -0.3694 0.3624 0.00 0.9851
Urban: Age-Group=1 vs Age-Group=5 -2.3809 -2.7905 -1.9714 -2.3809 0.2090 0.05 -2.7905 -1.9714 129.83 <.0001
Urban: Age-Group =2 vs Age-Group =5 -0.3044 -0.6022 -0.0066 -0.3044 0.1520 0.05 -0.6022 -0.0066 4.01 0.0451
Urban: Age-Group =3 vs Age-Group =5 1.1043 0.8162 1.3924 1.1043 0.1470 0.05 0.8162 1.3924 56.43 <.0001
Urban: Age-Group =4 vs Age-Group =5 -0.2372 -0.5128 0.0384 -0.2372 0.1406 0.05 -0.5128 0.0384 2.85 0.0916
Rural: Age-Group =1 vs Age-Group =5 -2.3333 -3.2211 -1.4455 -2.3333 0.4530 0.05 -3.2211 -1.4455 26.53 <.0001
Rural: Age-Group =2 vs Age-Group =5 -1.2011 -1.8444 -0.5578 -1.2011 0.3282 0.05 -1.8444 -0.5578 13.39 0.0003
Rural: Age-Group =3 vs Age-Group =5 -0.3924 -0.9839 0.1991 -0.3924 0.3018 0.05 -0.9839 0.1991 1.69 0.1935
Rural: Age-Group =4 vs Age-Group =5 -0.3817 -0.9477 0.1843 -0.3817 0.2888 0.05 -0.9477 0.1843 1.75 0.1863
